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Type 2 Diabetes 
 
Type 2 diabetes mellitus (T2DM) is the most common metabolic disease in 
the world. The westernization of the diet and sedentary lifestyle are the 
most responsible factors that drive to insulin resistance and T2DM. 
Maintenance of glucose homeostasis depends on a complex interplay 
between the insulin responsiveness of skeletal muscle, liver, adipose 
tissue and glucose-stimulated insulin secretion by pancreatic beta cells. 
Defects in these organs are responsible for insulin resistance and 
progression to hyperglycemia. 
In addition to the major health consequences to individuals, including 
higher risk of death, heart disease, stroke, kidney disease, blindness, 
amputations, neuropathy, and pregnancy-related complications, diabetes 
and its complications result in a total huge cost in the Public Health. 
Unfortunately, the incidence of diabetes has more than doubled in the 
past 25 yr, with 1.6 million new cases diagnosed in adults in 20071,2 and a 
projected increase of 165% from 2000 to 20503. 
Closely linked with the rise in diabetes prevalence is the rapidly increasing 
epidemic of obesity around the world, predominantly in developed 
societies4. In 2004, 17% of children in the United States between ages 2 
and 19 yr were overweight, and 32% of adults over age 20 were obese5. 
Both obesity and related inactivity are likely to contribute to the 
pathogenesis of diabetes because the incidence of diabetes can be 
reduced by modest weight loss and exercise6-8. In light of these findings, 
an important public health goal should be to understand the complex 
pathophysiology of diabetes and to identify and target specific 
mechanisms to prevent DM in at-risk individuals. 
 
 
 
Risk factors associated with type 2 diabetes 
 
Multiple physiological abnormalities can be found in individuals with 
established type 2 DM, defined on the basis of elevations in fasting and/or 
postprandial glucose2. These include insulin resistance in muscle and 
adipose tissue, β-cell dysfunction leading to impaired insulin secretion, 
increased hepatic glucose production, abnormal secretion and regulation 
of hormones, and altered balance of central nervous system pathways 
controlling food intake and energy expenditure. Given all these diverse 
abnormalities in multiple tissues and the secondary consequences of 
established hyperglycemia and hyperlipidemia, it is difficult to identify the 
primary events that lead to the development of diabetes. 
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Risk factors for the development of and/or progression of type 2 DM 
include: 
1) genetics9-15, exemplified by the high risk of type 2 DM in particular 
ethnic groups16 and the high concordance rates in monozygotic twin 
pairs17 and 
2) both prenatal and postnatal environmental factors, including 
suboptimal intrauterine environment18,19, low birth weight18,20, obesity21, 
inactivity22, gestational diabetes23, and advancing age24. 
Several studies have indicated that insulin resistance is common in high-
risk individuals years before the onset of type 2 DM25-27. 
Multiple mechanisms have recently emerged as potential causes of insulin 
resistance and/or diabetes progression, among them impaired 
mitochondrial capacity and/or function, altered insulin signaling due to 
cellular lipid accumulation, proinflammatory signals, and endoplasmic 
reticulum stress and reduced incretin-dependent and -independent β-cell 
insulin secretion. 
 
The biology of mitochondria 
 
Mitochondria are double-membrane organelles that serve multiple 
essential cellular functions (Fig. 1) mediated by thousands of 
mitochondrial-specific proteins encoded by both the nuclear and 
mitochondrial genomes28,29. Although mitochondria are most often 
recognized for their role in generating the majority of cellular ATP via 
oxidative phosphorylation (OXPHOS), other essential metabolic functions 
include the generation by the tricarboxylic acid (TCA) cycle of numerous 
metabolites that function in cytosolic pathways, oxidative catabolism of 
amino acids, ketogenesis, ornithine cycle activity ("urea cycle"), the 
generation of reactive oxygen species (ROS) with important signaling 
functions30,31, the control of cytoplasmic calcium32,33, and the synthesis of 
all cellular Fe/S clusters, protein cofactors essential for cellular functions 
such as protein translation and DNA repair34. The rate-limiting first step in 
steroidogenesis also occurs in mitochondria, thus linking mitochondrial 
function to endocrine homeostasis35-37. This multiplicity of organelle 
functions explains the variability in pathophysiology, severity, and age of 
onset of the increasing number of diseases recognized to arise from 
primary or secondary alterations in specific mitochondrial pathways34,38-40. 
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Figure 1. basic structure of the mitochondrion. 
 
 
The mitochondrial matrix also contains the circular mitochondrial DNA 
(mtDNA) molecules, normally inherited exclusively from the mother, 
which encodes for 37 genes (13 of which are subunits of the ETC). 
Translation of these proteins occurs within the mitochondrial matrix, 
utilizing mtDNA-encoded rRNA and tRNA (Fig. 2). 
 
 
 
Figure 2. The two strands of mtDNA are differentiated by their nucleotide 
content with the guanine rich strand referred to as the heavy strand, and 
the cytosine rich strand referred to as the light strand. The heavy strand 
encodes 28 genes, and the light strand encodes 9 genes for a total of 37 
genes. Of the 37 genes, 13 are for proteins (polypeptides), 22 are for 
transfer RNA (tRNA) and two are for the small and large subunits of 
ribosomal RNA (rRNA). 
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The morphology of mitochondria 
 
In the thin sections observed by electron microscopy, mitochondria 
appear as discrete, small, double-membrane organelles. However, more 
recent studies based on light microscopy in live cells have revealed that 
mitochondria exist as a reticulum that is in continuous communication 
through dynamic fusion and fission events, moving actively to different 
regions of the cell through interactions with the cytoskeleton. The 
mitochondrial reticulum is composed of an outer and an inner membrane, 
between which is the intermembrane space, and a matrix limited by the 
inner membrane (Fig. 3). The area of the inner membrane can be greater 
than that of the outer membrane due to the presence of cristae, inner 
membrane invaginations that contain all the transmembrane proteins of 
the electron transport chain (ETC) as well as the mitochondrial ATPase41-
43. The mitochondrial matrix contains the components of the TCA cycle 
and of the β-oxidation pathway, which provide reduced nicotinamide 
adenine dinucleotide (NADH) and reduced flavin adenine dinucleotide 
(FADH2) to the Electron Transport Chain (ETC). 
 
 
 
Figure 3. The mitochondrial reticulum is composed of an inner and outer 
membrane, between which lies the intermembrane space, and a matrix 
contained within the inner membrane. The surface of the inner membrane 
is folded into cristae. The organization and distribution of the 
mitochondrial reticulum is controlled by interactions with cytoskeletal 
elements such as microtubules. The matrix contains the enzymatic 
machinery for fatty acid β oxidation, which generates acetyl-CoA from acyl 
chains, and reducing equivalents in the form of NADH and FADH2. 
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The electron transfer chain (ETC) 
 
The ETC is composed of five large multisubunit complexes (complexes I to 
V) with more than 85 individual gene products. The ETC transports 
electrons from donors (NADH at complex I, FADH2 at complex II) to a final 
acceptor, molecular oxygen, forming H2O at complex IV (Fig. 4). The 
transport of electrons is accompanied by release of large amounts of free 
energy, most of which is harnessed for the translocation of protons from 
the matrix to the intermembrane space; the remainder is dissipated as 
heat (Fig. 5). The energy contained in the proton electrochemical gradient 
generated by the ETC is then coupled to ATP production as protons flow 
back into the matrix through the mitochondrial ATPase which constitutes 
the complex V. Thus, OXPHOS results from electron transport, the 
generation of a proton gradient, and subsequent proton flux coupled to 
the mitochondrial ATPase. Each of these steps can vary in efficiency; for 
example, the exact stoichiometry between electron flow and proton 
pumping, or between proton pumping and ATP synthesis varies depending 
on the probability of loss of electrons from the ETC before reaching 
complex IV and on non-ATPase-coupled proton leak through the inner 
mitochondrial membrane, for example via uncoupling proteins (UCPs) 
(Fig. 5). 
 
 
 
Figure 4. Schematic representation of the Electron Transfer Chain. 
Electrons derived from reduced donors NADH and FADH2 are transported 
within the ETC to molecular oxygen, producing water. The flow of 
electrons within the ETC is coupled to translocation of protons due to the 
large amount of free energy released during electron transport. The 
remainder of this free energy is released as heat. The proton gradient 
thus produced is dissipated through the mitochondrial ATPase, and the 
consequent decrease in free energy drives ATP synthesis. This process is 
known as OXPHOS, or coupled respiration. 
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Figure 5. Under circumstances where NADH and FADH2 are available, but 
movement of electrons down the respiratory chain is slow, some of those 
electrons will be released from the respiratory chain and reduce molecular 
oxygen, forming the superoxide anion O2–, hydrogen peroxide, and the 
hydroxyl radical OH–. These are the main ROS formed at steady state. 
Accumulation of ROS activates UCPs, which dissipate the proton gradient 
without producing ATP, resulting in uncoupled respiration. 
 
 
Mechanisms regulating mitochondrial density and activity 
 
The term mitochondrial biogenesis is often used to describe the new 
generation of mitochondria in response to increased energy demands, or 
the increase of mitochondria necessary for cell growth and division. 
However, the copy number of specific mitochondrial proteins and the 
functional capacity of each distinct mitochondrial pathway may be very 
variable between different tissues and between different physiological 
conditions. Thus, the term mitochondrial biogenesis can be ambiguous 
because of multiple parameters, including mtDNA copy number, 
mitochondrial density, levels of specific mitochondrial proteins, and 
mitochondrial functional output may vary independently of each other. 
For example, the proliferation of mitochondria occurring to sustain 
hyperplastic growth is probably very different from that occurring to 
support hypertrophic growth in any given tissue, and the regulatory 
mechanisms controlling these adaptive changes are likely to be distinct. 
Although it is know very little about specific mechanisms that control 
different modalities of mitochondrial biogenesis, it is clear that these 
mechanisms require coordination between the nuclear and mitochondrial 
genomes. Transcription of the mitochondrial genome is under the control 
of a single transcription factor, TFAM, which is encoded by the nuclear 
genome. In turn, TFAM expression is regulated by the transcription factors 
NRF (nuclear respiratory factor)-1 and NRF-2, which specifically activate 
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numerous nuclear-encoded genes involved in mitochondrial 
respiration44,45. Thus, through NRF-stimulated expression of TFAM, the 
transcription of the mitochondrial genome is stimulated in coordination 
with that of nuclear-encoded mitochondrial genes. The expression of 
many other mitochondrial genes is controlled by additional nuclear 
transcription factors, including peroxisome proliferator-activated receptor 
(PPAR) α, PPARδ, estrogen-related receptor (ERR) α/γ, and Sp1, which can 
induce expression of mitochondrial genes in a tissue-dependent and 
physiological context-dependent manner46. 
A high level of transcriptional coordination is required to ensure coupling 
of mitochondrial activity to other metabolic activities within the cell. This 
coordination is accomplished through the action of transcriptional 
coactivators and corepressors. The best studied coactivators of 
mitochondrial gene transcription are members of the PPARγ coactivator 
(PGC) family, including PGC-1α , PGC-1β47,48, and PPRC, a related serum-
responsive coactivator49. These cofactors respond to cellular energy-
requiring stimuli46 to activate transcription factors promoting 
mitochondrial remodeling and/or biogenesis. For example, PCG-1α is 
highly expressed in muscle, liver, and brown fat, and expression is further 
increased in these tissues in response to exercise, fasting, and cold 
exposure, respectively. Although PGC-1α and PGC-1β do not appear to be 
required for mitochondrial biogenesis during development50, they are 
necessary for the expression of the full complement of proteins of 
mitochondrial OXPHOS and fatty acid β-oxidation pathways in muscle and 
brown adipose tissue50-60.  
Forced expression studies in adipogenic and myogenic mammalian cell 
lines demonstrated that PGC-1α markedly induces the expression of NRF-
1, NRF-2, and Tfam47 PGC-1α can also interact directly with and coactivate 
NRF-1 on the Tfam gene promoter. Studies in primary cardiac myocytes in 
culture and in the hearts of transgenic mice have demonstrated that 
overexpression of PGC-1α up-regulates the expression of genes involved 
in mitochondrial fatty acid oxidation, most of which are PPARα targets, in 
addition to NRF-1 targets61. Cardiac-specific overexpression of PGC-1α in 
transgenic mice leads to massive mitochondrial proliferation, ultimately 
resulting in cardiomyopathy and death61. Interestingly, in neonatal cardiac 
myocytes in culture, PGC-1α induces mitochondria that support largely 
coupled respiration consistent with the known ATP-generating function of 
this organelle in heart61. Lastly, forced expression of PGC-1α in skeletal 
muscle of transgenic mice triggers mitochondrial proliferation and the 
formation of mitochondrial-rich type I, oxidative (“slow-twitch”) muscle 
fibers62. Collectively, these results indicate that PGC-1α is capable of 
promoting mitochondrial biogenesis through its coactivating effects on key 
factors such as NRF-1. 
Moreover, PGC-1α and PGC-1β are crucial for the rapid bursts in 
mitochondrial proliferation that accompany perinatal heart and brown 
adipose tissue development50. These data support the concept that 
mitochondrial adaptation to specific energy demand is mediated by PGC-
1α and PGC-1β; by contrast, mitochondrial expansion during cell 
proliferation is more likely to depend on serum-responsive coactivators 
such as PPRC63. 
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The role of corepressors in the transcriptional control of energy 
metabolism genes is less extensively studied. However, evidence in 
cultured cells and in mouse models points to a critical role of the 
corepressor RIP140 in controlling important aspects of mitochondrial 
energy metabolism in both adipose tissue and muscle63-68. 
RIP140 is highly expressed in metabolic tissues66, and further 
understanding of its biological role has been greatly improved through the 
use of loss-of-function mouse model. The RIP140-null animals show that 
RIP140 is essential for female fertility69,70 and plays a crucial role in lipid 
metabolism. In fact, RIP140-null mice are extremely lean and exhibit 
resistance to obesity and hepatic steatosis as well as enhanced glucose 
tolerance and enhanced responsiveness to insulin when compared with 
matched wild-type littermates fed a high-fat diet66. Adipogenesis is 
unaffected in these mice, and expression profiling identified genes 
involved in catabolism in white adipose tissue as well as in skeletal 
muscle. 
In 3T3-L1 adipocytes, depletion of RIP140 recapitulates the alterations in 
gene expression, observed in vivo, affecting clusters of genes implicated 
in glucose uptake, glycolysis, TCA cycle, β-oxidation, mitochondrial 
biogenesis, oxidative phosphorylation, and mitochondrial uncoupling71. 
The modulation of RIP140 expression may also affect the metabolic 
properties of skeletal muscle72,73. This suggests that RIP140 could serve 
an important function in terminally differentiated adipocytes and 
myotubes; in the RIP140-null animals, muscles exhibited a marked 
increase in mitochondrial activity accompanied by a consequent shift in 
myofibers towards the more oxidative types. On the other hand, in the 
transgenic animals, the higher expression of RIP140 resulted in a 
decrease in both mitochondrial activity and the number of oxidative 
myofibers. Moreover, RIP140 mRNA levels are higher in glycolytic 
muscles, extensor digitorum longus (EDL) and gastrocnemius, than in 
oxidative muscles, soleus and diaphragm, suggesting a role for RIP140 as 
an inhibitor of oxidative metabolism in skeletal muscle73. 
Finally, RIP140 suppresses UCP1 through interaction with specific 
enhancer elements and also suppresses expression of genes involved in β-
oxidation and respiratory chain assembly. RIP140 also interacts directly 
with many of the transcription factors and cofactors coactivated by PGC-
1α73. 
The mechanisms that control the balance between PGC-1 coactivators and 
RIP140 and other corepressors are not completely clear yet but probably 
represent key regulatory mechanisms of energetic adaptation. 
 
 
Tissue-specific contexts: role of mitochondria 
 
Skeletal Muscle 
 
Mitochondria are particularly important for skeletal muscle function, given 
the high oxidative requests imposed on this tissue by contraction. 
Mitochondria play a critical role in giving sufficient levels of ATP needed; 
this high-level requirement for ATP by sarcomeres has likely contributed 
to the distinct subsarcolemmal and sarcomere-associated populations of 
mitochondria in muscle. Moreover, muscle cells must maintain metabolic 
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flexibility, defined as the ability to rapidly modulate substrate oxidation as 
a function of ambient hormonal and energetic conditions. For example, 
healthy muscle tissue predominantly oxidizes lipid in the fasting state, as 
evidenced by low respiratory quotient (RQ), with subsequent transition to 
carbohydrate oxidation (increased RQ) during the fed state. Availability of 
fuels, particularly lipids, and capacity to oxidize them in the mitochondria 
are also critical for sustained exercise. Thus, mitochondrial functional 
capacity is likely to directly affect muscle metabolic function and, because 
of its large contribution to total body mass, to have a significant impact on 
whole-body metabolism. This possibility is supported by the findings of 
increased mitochondrial content in skeletal muscle in an individual with 
hypermetabolism and resistance to weight gain (Luft syndrome)74. 
Skeletal muscle is the largest insulin-sensitive organ in humans, 
accounting for more than 80% of insulin-stimulated glucose disposal. 
Thus, insulin resistance in this tissue has a major impact on whole-body 
glucose homeostasis. Indeed, multiple metabolic defects have been 
observed in muscle from insulin-resistant but normoglycemic subjects at 
high risk for diabetes development, including reduced insulin-stimulated 
glycogen synthesis25,75,76, alterations in insulin signal transduction77; and 
increased muscle lipid accumulation78. Although it remains unclear 
whether any of these defects play a causal role in insulin resistance, 
intramuscular lipid excess strongly correlates with the severity of insulin 
resistance, even after correction for the degree of obesity78, and has been 
observed in muscles of multiple fiber types79. Moreover, lipid excess has 
been linked experimentally to induction of insulin resistance80 and 
alterations in insulin signal transduction81-83. 
Thus, one possible mechanism by which impaired mitochondrial function 
might contribute to insulin resistance is through altered metabolism of 
fatty acids. Increased tissue lipid load, as with obesity, and/or sustained 
inactivity, may lead to the accumulation of fatty acyl coenzyme A (CoA), 
diacylglycerols, ceramides, products of incomplete oxidation, and ROS, all 
of which have been linked experimentally to reduced insulin signaling and 
action80-86. Additional mechanisms potentially linking impaired 
mitochondrial oxidative function to insulin resistance include reduced ATP 
synthesis for energy-requiring functions such as insulin-stimulated glucose 
uptake, abnormalities in calcium homeostasis (necessary for exercise-
induced glucose uptake)87-89 and reduced ATP production during 
exercise90, potentially contributing to reduced aerobic capacity, muscle 
weakness, and decreased voluntary exercise. 
 
 
Evidences for muscle mitochondrial dysfunction in DM 
 
An important early evidence suggesting that muscle mitochondrial 
oxidative dysfunction may be associated with insulin resistance in humans 
was the series of observations by Simoneau and Kelley that obesity is 
associated with reductions in citrate synthase, malate dehydrogenase, 
carnitine palmitoylotransferase 1 (CPT1), and cytochrome oxidase (COX) 
activity in the fasting state91 and with parallel increases in activity of the 
glycolytic enzymes hexokinase and phosphofructokinase92. Moreover, 
oxidative activity (e.g., citrate synthase, acyl CoA dehydrogenase) is a 
robust correlate of insulin sensitivity, even better than either in 
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triglycerides or long-chain fatty acyl CoA93. Impaired metabolic flexibility 
also correlates with intramyocellular accumulation of lipids91, and 24-h RQ 
can predict subsequent weight gain93,94. Together, these data suggest that 
an intrinsic defect in multiple components of oxidative metabolism, or 
altered regulation, may contribute to the development of both obesity and 
insulin resistance. 
The diminished capacity for appropriate regulation of oxidative 
metabolism observed in the above studies could be linked to reduced 
mitochondrial function due to abnormal mitochondrial density and/or in 
vivo function and/or intrinsic defects in oxidative metabolism of lipids or 
other substrates. Multiple studies suggest that human insulin resistance is 
indeed accompanied by impaired in vivo mitochondrial oxidative function 
linked, at least in part, to reduced mitochondrial density. Boushel et al.95 
found modest reductions in ADP and succinate-stimulated oxygen 
consumption in permeabilized muscle fibers from obese individuals with 
type 2 DM. In this study, the differences in oxidative capacity did not 
remain after normalization for mitochondrial mass by citrate synthase 
activity or mtDNA content, suggesting that reduced mitochondrial mass 
might be a major contributor. 
Nuclear magnetic resonance (NMR) spectroscopy has also been used to 
assess mitochondrial function in vivo, with studies finding similar 
reductions in oxidative function in both insulin resistance and type 2 DM. 
For example, rates of mitochondrial OXPHOS in offspring of type 2 
diabetic subjects, as assessed by 31P spectroscopy, are reduced by 30% in 
the fasting state96. The magnitude of this change is strikingly similar to 
the 38% lower muscle mitochondrial density, assessed by electron 
microscopy, in this same population, suggesting once again that 
decreased mitochondrial density might be an important factor in reduced 
oxidative capacity in subjects with a family history of diabetes. 
Alterations in mitochondrial function have also been identified in isolated 
mitochondria from humans with insulin resistance and DM. Mogensen et 
al.97 observed decreases in maximal ADP-stimulated respiration (state 3, 
malate and pyruvate as substrates) in mitochondria isolated from obese 
subjects with DM as compared with obesity alone; these differences 
persisted even after normalization to citrate synthase activity. Thus, these 
data suggest that in addition to decreased mitochondrial density, there 
are additional intrinsic defects in TCA cycle, OXPHOS, membrane 
potential, or adenine nucleotide transporters in mitochondria of individuals 
with established diabetes. 
Analysis of global gene expression patterns has also demonstrated a 20–
30% reduction in mRNA expression levels for multiple nuclear-encoded 
genes of the OXPHOS pathway in humans with type 2 DM98-100. 
Importantly, similar reductions in OXPHOS gene expression have been 
observed in some, but not all, populations of insulin-resistant, but 
completely normoglycemic, individuals99,101. 
A recent study of Asian Indian subjects found no correlation between 
changes in OXPHOS gene expression and insulin resistance102. In these 
individuals, expression of OXPHOS and TCA cycle genes, mtDNA content, 
and ATP production rates were actually higher in both non diabetic and 
diabetic individuals compared with Northern European controls, despite 
lower overall insulin sensitivity. However, circulating triglycerides were 
significantly elevated in both non diabetic and diabetic individuals of Asian 
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Indian origin102. These observations also raise the question of whether 
levels of OXPHOS gene expression and function have to be considered 
relative to the oxidative fuel load in an individual. For example, high 
OXPHOS expression in the population mentioned above may still be not 
enough for appropriate and complete oxidation of a chronic high load of 
circulating lipids, while lower OXPHOS levels may be sufficient under 
conditions of a low circulating lipid load. 
Such data also arise the importance of considering additional aspects of 
oxidative mitochondrial function beyond OXPHOS expression or capacity. 
For example, primary myotubes isolated from obese humans with type 2 
DM display reduced basal lipid oxidation and insulin-stimulated glucose 
oxidation with no differences in OXPHOS gene expression103. Thus, defects 
in lipid oxidation in DM can be significant contributors to disfunctional 
oxidative metabolism even in the absence of detectable alterations in 
OXPHOS gene expression or function. 
 
 
Factors affecting OXPHOS gene expression in muscle 
 
Reduced OXPHOS gene expression has been observed in response to 
genetic and nutritional obesity104, short-term high-fat feeding (even in 
humans)105, lipid infusion106, and lipid loading of myotubes104. However, 
these responses are not observed in all studies of high-fat feeding; in fact, 
some studies demonstrate that high-fat feeding is associated with 
increased numbers of mitochondrial protein and DNA content, potentially 
mediated by chronic fatty acid activation of PPARs107-109. These studies 
suggest that genetic background104, age at dietary intervention, specific 
dietary lipid composition, and duration of diet may be important variables 
to consider when analyzing the interaction between OXPHOS gene 
expression and diet. Moreover, alterations in OXPHOS gene expression 
may be a secondary response to an underlying primary defect in oxidative 
metabolism, reflecting attempts to compensate the reduction in 
mitochondrial capacity. 
Reduced physical activity could be associated with reduced muscle 
OXPHOS gene expression. In rats bred for low aerobic capacity over 
multiple generations, expression of several OXPHOS genes is markedly 
reduced, even in the absence of obesity110. Conversely, OXPHOS 
expression can be increased with exercise training111,112, a potent insulin 
sensitizer. 
Finally, genetic and epigenetic modifications may also contribute to 
reduced expression of OXPHOS genes in type 2 DM. For example, 
expression of COX7A1, a complex IV gene down-regulated in type 2 DM, 
is heritable (50–72% heritability, as assessed by analysis in monozygotic 
and dizygotic twins), indicating a strong genetic or shared familial 
environmental contribution113. Similar patterns are observed for the 
complex I gene NDUFB6114 and the ATP synthase component ATP5O115. 
Indeed, expression of nuclear-encoded OXPHOS genes is significantly 
more concordant between monozygotic twins than expected and is the 
top-ranking gene set for concordance in pathway analysis of global gene 
expression. Mediators of mitochondrial biogenesis, including ERRα, may 
contribute to the strong heritability of OXPHOS components. 
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Epigenetic mechanisms may also contribute to these patterns because 
reduced expression parallels increased DNA methylation of both the 
COX7A1 promoter113 and NDUFB6114,116. 
As for the other tissues, the expression of OXPHOS genes in muscle is 
mediated in part by the action of coactivators and corepressors. PGC-1α 
has been recognized as an important coactivator in skeletal muscle, 
contributing to fiber type determination, glucose uptake, and oxidative 
capacity. Moreover, alterations in muscle PGC-1α or β mRNA expression 
are observed in humans with insulin resistance, being reduced by nearly 
50% in muscle from individuals with diabetes99 and in some populations of 
normoglycemic insulin-resistant humans98,101,114. In turn, PGC-1α 
expression may also be reduced as a consequence of promoter 
methylation117 or caused by insulin itself, obesity, and sustained lipid 
exposure103. For example, saturated fatty acids reduce PGC-1α promoter 
transcriptional activity and expression in cultured myotubes, in parallel 
with reduced OXPHOS expression and O2 consumption104. PGC-1 activity 
can also be modulated at the level of translation and by 
posttranscriptional changes, including inhibitory acetylation mediated by 
GCN5118 and deacetylation by SIRT1 action119. These multiple modes of 
PGC-1α regulation are likely to have evolved from the need to set 
mitochondrial energy metabolism in response to different inputs. 
 
In summary, insulin resistance has been associated with alterations in 
skeletal muscle mitochondrial oxidative function and its transcriptional 
regulatory pathways. However, several lines of evidence suggest that this 
may not be a causal relationship in all situations. First, oxidative 
dysfunction is not observed in all insulin resistant individuals102. Second, 
oxidative activity is determined by the need to generate energy in 
response to cellular demands, such as contraction and ion transport; thus 
oxidative capacity is not likely to be limiting in the resting state in muscle. 
Rather, alterations in relative utilization of substrates, an imbalance 
between fuel load and cellular energy requirements, and/or differential 
thresholds for generation of or resolution of oxidative stress in this setting 
may contribute to differential susceptibility to insulin resistance in muscle. 
 
 
Adipose tissues 
 
The role of mitochondria in adipose tissue is most apparent in brown 
adipose tissue, where flux through the ETC generates heat in the process 
of thermogenesis, a potentially important mechanism regulating systemic 
metabolism even in adult humans120-123. In brown fat, electron transport is 
greatly accelerated due to tissue-specific expression of the mitochondrial 
UCP1. UCP1 dissipates the proton gradient of sufficient degree to sustain 
the synthetic activity of the mitochondrial ATPase121,124-126, thus driving 
continuous accelerated electron transport. UCP1-mediated uncoupling 
alone, however, can not fully account for the large thermogenic capacity 
of brown adipocytes in the absence of mechanisms that ensure continuous 
substrate delivery to the ETC. Thus, brown adipocyte mitochondria also 
contain high levels of CPT1b, which is critical for the entry of fatty acids 
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into the mitochondria. β-Oxidation, in turn, generates large amounts of 
reducing equivalents for the ETC. 
In contrast, white adipocytes have been described to contain less 
mitochondria compared with brown adipocytes or muscle. However, 
mitochondrial density increases dramatically, and mitochondrial 
remodeling occurs during white adipocyte differentiation127-129, suggesting 
that mitochondrial functions are required to support the multiple biological 
roles of mature white adipocytes. Interestingly, a recent compendium of 
mitochondrial proteins from 14 different mouse tissues indicates that 
white adipocyte mitochondria contain a more diverse protein repertoire 
than mitochondria from heart, skeletal muscle, or brain28. Thus, white 
adipocyte mitochondria appear to be equipped for a broader array of 
functions compared with mitochondria in tissues that must sustain rapid 
bursts of energy-requiring processes. Among the mitochondrial functions 
that may be relevant for white adipose tissue function are the anaplerotic 
generation of metabolic intermediates for fatty acid synthesis and 
esterification130, the maintenance of a robust pathway for the folding and 
secretion of high abundance circulating proteins such as adiponectin131, 
and interactions between mitochondrial function and components of the 
insulin signaling pathway131. 
 
 
Adipose tissue mitochondrial activity and insulin resistance 
 
The large capacity of brown adipose tissue mitochondria to oxidize fatty 
acids results in a considerable impact on whole-body metabolism; 
increased brown adipose tissue abundance correlates negatively with fuel 
storage and weight gain in rodents, and vice versa132. 
Recent works have led to reconsideration of the role of brown fat in the 
balance of energy metabolism, underlining that humans possess adipose 
tissue depots that are cold-sensitive and hypermetabolic, as assessed by 
their very high uptake of labeled glucose123,133. Such depots appear to be 
less active as a function of aging and/or obesity122,134-137. Thus, impaired 
mitochondrial capacity in brown adipose tissue might be functionally 
linked to impaired thermogenesis and energy expenditure, and thus 
increased susceptibility to obesity-linked insulin resistance. 
The relevance of white adipocyte mitochondria to whole-body metabolism 
and metabolic disease may depend on the extent to which mitochondrial 
respiratory capacity and/or the total mass of white adipose tissue would 
be sufficient to impact circulating free fatty acid levels. White adipocytes 
display a high degree of plasticity138, and regional differences in metabolic 
activity can be linked to varying mitochondrial density139. Higher 
mitochondrial density and even UCP1 can be induced in response to 
pharmacological or genetic alterations of white adipocytes139-148, 
suggesting that white adipose tissue could potentially be induced to 
acquire more oxidative metabolic phenotypes, promoting increased fuel 
consumption and thus energy expenditure. Whether respiratory chain 
uncoupling mediated through the induction of UCP1 in white adipocytes 
alone could reduce free fatty acid release, or whether an additional 
increase in mitochondrial oxidative capacity would be required, is still an 
open discussion149-153. 
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In addition to the effects on fuel utilization, decreased mitochondrial 
capacity in adipocytes may also alter adipocyte insulin sensitivity and/or 
function due to the high energetic requirements for fatty acid storage, 
adipokine secretion131, insulin signaling154, and glucose uptake. 
Interestingly, in cultured adipocytes, impairment of respiratory chain 
function through depletion of Tfam during adipocyte differentiation results 
in impaired insulin-stimulated glucose transport154. 
 
 
Evidences for adipose tissue mitochondrial dysfunction in DM 
 
White adipocyte mitochondrial content is decreased in both rodent and 
human obesity147,155-158 and correlates with insulin resistance that 
accompanies obesity. In humans, white adipocyte mtDNA copy number is 
inversely correlated with age and BMI and directly correlated with basal 
and insulin-induced lipogenesis159. Thus, reduced mtDNA content could 
reduce adipocyte capacity for lipid storage, promoting ectopic lipid 
accumulation in peripheral tissues such as muscle and liver. In parallel, 
the expression of nuclear-encoded OXPHOS genes is down-regulated in 
visceral adipose tissue of humans with type 2 DM160. Administration of 
thiazolidinediones induces changes in mitochondrial content and 
remodeling in white adipocytes concomitantly with an improvement in 
insulin sensitivity140,143,147,157,161-165. Mitochondrial levels in white 
adipocytes are also increased in response to adrenergic stimulation, β-3 
agonists, and CB1 blockade in mice162,166,167 with consequent increased 
insulin sensitivity. 
 
At the moment it is still unclear if changes in mitochondrial density are a 
cause or consequence of changes in insulin sensitivity, however, some 
evidences suggest that lack of insulin signaling does not reduce 
mitochondrial capacity in adipose tissue. For example, conditional KO mice 
in the adipose tissue for the insulin receptor (FIRKO mice) display high 
levels of mitochondrial genes involved in fatty acid oxidation and OXPHOS 
over the lifespan of the animals168. Thus, mechanisms that induce and 
maintain active mitochondria in adipocytes can bypass defects in insulin 
signaling, and indeed, insulin signaling may repress mitochondrial gene 
expression and/or function. 
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Towards the Brown Fate 
 
The genetic program leading to brown adipose tissue development, and 
potentially to the high abundance of mitochondria, is initiated by the zinc-
finger protein PRDM16168-171. Recent articles sustain the hypothesis that 
brown adipocytes and myocytes share a common cellular lineage; in 
addition, the transcriptional coactivators PGC-1α and -β47 play a critical 
role in the expansion of the mitochondrial reticulum and in the induction 
of UCP1 and the brown adipose tissue thermogenic program during the 
perinatal period50. 
Adipocyte mitochondrial density and OXPHOS activity can be regulated in 
response to factors that affect lipid metabolism. For example, Toh et al.146 
and Nishino172 et al. find that mice deficient in Fsp27 (also called Cidec) a 
lipid droplet protein that promotes lipid storage in white and brown 
adipocytes, have increased whole-body energy expenditure, resistance to 
diet-induced obesity, and enhanced insulin sensitivity. This apparent 
paradoxical result (high insulin sensitivity despite deficiency in lipid 
storage), appears to be due to the increased mitochondrial density and 
activity in white adipocytes, which are brown-like in their increased 
capacity to oxidize large quantities of fatty acids. Nitric oxide production 
by the endothelial nitric oxide synthase has also been linked to enhanced 
adipose tissue mitochondrial biogenesis and prevention of high-fat diet-
induced obesity167. Conversely, both genetic and diet-induced obesity 
result in decreased mitochondrial density and OXPHOS activity in adipose 
tissue104,147,156-158, potentially contributing to adipose tissue dysfunction 
and exacerbation of insulin resistance. The mechanisms by which obesity 
results in a reduction in adipose mitochondrial density are not known but 
could be mediated by decreased expression of PGC-1α, as observed in 
obese humans173. 
Finally, Nedergaard and collegues examining precursors from the purest 
white adipose tissue depot (epididymal), reported that chronic treatment 
with the peroxisome proliferator activated receptor γ agonist rosiglitazone 
promotes not only the expression of PGC-1α and mitochondriogenesis in 
these cells but also a norepinephrine-augmentable UCP1 gene expression 
in a significant subset of the cells, providing these cells with a genuine 
thermogenic capacity. These cells probably constitute a subset of 
adipocytes (called “brite” adipocytes) with a developmental origin and 
molecular characteristics distinguishing them as a separate class of cells, 
since they remain negative for the classical markers of brown adipocytes 
(Zic1, Lhx8, Meox2, and characteristically PRDM16) or of myocytes 
(myogenin and myomirs, muscle-specific microRNAs) and retain white fat 
characteristics such as Hoxc9 expression148. 
 
 
Liver 
 
The liver plays a central, unique role in carbohydrate, protein, and fat 
metabolism. It is critical for maintaining glucose homeostasis during fuel 
availability, via storage of glucose as glycogen or conversion to lipid for 
export and storage in adipose tissue, and in the fasting state, via 
catabolism of glycogen, synthesis of glucose and ketogenesis. In turn, 
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these responses are regulated by the key hormones insulin and glucagon, 
which modulate signaling pathways and gene expression, leading to 
inhibition or stimulation of glucose production, respectively. 
Recent human data have highlighted the importance of disordered hepatic 
metabolism, including inappropriately increased hepatic glucose 
production, hyperlipidemia, and lipid accumulation, in both obesity and 
type 2 DM174. Similarly, rodent data also support an important role for the 
liver in diabetes pathogenesis. Liver-specific insulin receptor knockout 
(LIRKO) mice develop insulin resistance, glucose intolerance, impaired 
insulin suppression of hepatic glucose production, and altered patterns of 
hepatic gene expression175. Interestingly, these mice are also dyslipidemic 
and susceptible to atherosclerosis176. Given the diverse array of unique 
metabolic functions centered in the liver, it is not surprising that 
ultrastructure and function of hepatic mitochondria are distinct from that 
of muscle. Electron microscopy demonstrates that mitochondrial area is 
44% lower in liver than in heart177 with smaller size, fewer cristae, and 
lower matrix density. Protein expression of multiple OXPHOS components 
and Tfam and citrate synthase activity are also lower in liver (e.g., 7% 
that of cardiac muscle)178. Despite lower OXPHOS capacity, state 3 
respiration and respiratory control ratio are equivalent in liver and muscle. 
By contrast, the content of mtDNA is actually higher in the liver than in 
other tissues. 
Impairments in mitochondrial number and/or oxidative function could 
potentially affect multiple cellular functions within hepatocytes, both 
directly (e.g., reduced ATP generation, alterations in oxidative stress, 
reduced capacity for fatty acid oxidation) and indirectly, via effects on 
energy-requiring processes, including gluconeogenesis, synthesis of urea, 
bile acids, cholesterol, proteins and detoxification.  
Hepatic lipid accumulation may result when adipose lipid storage capacity 
is exceeded, as in obesity or adipocyte dysfunction (e.g., 
lipodystrophy)179. Alternatively, lipid accumulation may reflect an 
additional imbalance between de novo hepatic lipogenesis and 
mitochondrial oxidative metabolism. Interestingly, hepatic lipid 
accumulation is also a robust predictor of not only hepatic, but also 
muscle and adipose insulin sensitivity180,181. Conversely, modest weight 
loss (about 8 kg) normalizes intrahepatic lipid in subjects with type 2 DM, 
in parallel with normalization of hepatic insulin sensitivity, even in the 
absence of changes in intramyocellular lipid accumulation or circulating 
adipocytokines182. 
Although these data highlight an intimate relationship between obesity, 
intrahepatic lipid metabolism, and insulin sensitivity in humans, 
mechanisms responsible for these links remain unclear. One possibility is 
that excessive hepatic lipid accumulation may play a central, pathogenic 
role in insulin resistance. This hypothesis comes from experimental lipid 
loading, which can induce hepatic insulin resistance. Transgenic mice 
expressing lipoprotein lipase in the liver have a 2-fold increase in hepatic 
triglyceride content and are insulin resistant183. 
A second possibility is that hepatic insulin resistance itself contributes to 
alterations in mitochondrial oxidative capacity. Indeed, a recent paper 
demonstrated that mice with hepatic insulin resistance due to deletions of 
the major insulin receptor substrates (IRS-1 and IRS-2) have impaired 
mitochondrial function and biogenesis, as demonstrated by reduced NADH 
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oxidation, reduced ATP production rates, reduced numbers of 
mitochondria per cell, reduced fatty acid oxidation, and increased hepatic 
triglyceride accumulation184. Mitochondrial dysfunction was reversed by 
deletion of Foxo1. These data indicate that normal insulin signaling, which 
inhibits Foxo1, is required for maintenance of normal mitochondrial 
function in this model. Finally, these data indicate that hepatic lipid 
accumulation and insulin resistance are intimately linked with 
mitochondrial oxidative dysfunction. 
In summary, mitochondrial oxidative activity can be considered as a key 
determinant underlying diabetes risk. In isolation, reductions in 
mitochondrial activity mediated by genetic factors (family history, 
ethnicity), epigenetic mechanisms, developmental exposures, and aging 
may not be sufficient to induce insulin resistance. However, when 
sustained fuel excess (e.g., resulting from overnutrition or impaired fat 
storage) exceeds energetic demands and/or oxidative capacity, and/or 
appropriate compensatory mechanisms are insufficient (e.g., due to 
inactivity or failure of mitochondria to adapt to higher cellular oxidative 
demands), a vicious cycle of insulin resistance and impaired insulin 
secretion can be initiated. Resulting lipid accumulation and oxidative 
stress can alter transcriptional responses and damage mitochondria, 
further reducing OXPHOS capacity, compounding the deleterious effects of 
fuel excess and increasing diabetes risk. Although the importance of the 
PGC-1 family of coactivators has been stressed thus far, it is likely there 
are many additional metabolic, transcriptional and epigenetic mechanisms 
by which mitochondrial function adapts to environmental demands. 
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The epigenetic concept 
 
Epigenetics can be defined as any inheritable influence on gene activity 
that does not involve a change in DNA sequence. In all eukaryotic cells, 
genomic DNA is folded and compacted by histone and non-histone 
proteins to form nucleosomes and a further structured and dynamic form, 
generally referred to as chromatin. DNA packaging must be considered as 
a way to store and retrieve information since it represents a dynamic 
switch between transcriptional “on-off” states that result in gene 
activation and gene silencing. The term euchromatin  refers to accessible 
and transcriptionally active nucleosomes, while heteterochromatin is 
composed by highly condensed genetic material. 
In general, the epigenetic control is accomplished by means of two major 
mechanisms: methylation of cytosine residues in the DNA sequence and 
modifications of histones and other chromatin-associated proteins. 
Referring to the latter mechanism, it has long been known that histone tail 
domains can be covalently modified by acetylation, phosphorylation, 
methylation at specific amino acid positions (fig. 6) in a way that 
regulates the contacts with the underlying DNA 185.  
More recently, it has become evident that acethylation, phosphorylation, 
and newly discovered modifications (e.g. ubiquitination and sumoylation) 
also occur at the level of other chromatin associated proteins, 
transcription factors, transcriptional coactivators and corepressors, thus 
modulating their function, and ultimately regulating gene transcription 
(fig. 6). 
 
 
 
 
Figure 6. Dynamics of DNA packaging. Post translational modifications of 
histone and non-histone proteins impose changes in the nucleosomal 
organization and represent the dynamic switch between transcriptional 
“on-off” states of chromatin (M_Tablecaption). 
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The Histone Code 
 
The term “histone code” was proposed in 2001 by Jenuwein and Allis 186 to 
define a marking system consisting of amino-terminal modifications of 
histone proteins. These modifications are then read by effector molecules, 
for example coactivators and corepressors of gene transcription, and 
translated into biological functions, including chromatin transcription. It 
has been suggested that these chromatin marks might function in a 
combinatorial manner, thus increasing their indexing potential or capacity. 
Altogether, this marking system considerably extends the information 
potential of the genetic code, and represents an important level of 
regulation in response to endogenous and exogenous stimuli. 
 
 
Chromatin Remodeling Enzymes 
 
As mentioned above, histones and chromatin-associated proteins are the 
targets of multiple post-translational modifications and several enzymes 
act on chromatin by introducing different post-translational modifications 
at specific amino acids. These modifications include methylation of 
arginine (R) residues; methylation, acetylation, ubiquitination, ADP-
ribosylation, and sumoylation of lysines (K); and phosphorylation of 
serines and threonines 187. A list of the human enzymes involved in the 
modification of chromatin is reported in table 1. 
A single histone protein presents several residues that can undergo post-
tranlational modification giving rise to a variety of modified products. An 
example of this complexity is given by the peptide mass fingerprinting of 
core histones by mass spectrometric analysis that is able to detect 
methylation, acetylation, phosphorylation and ubiquitination. This analysis 
revealed the presence of 13 modification sites in histone H2A, 12 
modification sites in histone H2B, 21 modification sites in histone H3, and 
14 modification sites in histone H4 188. Each site can either be unmodified 
or modified. In addition, some lysine residue can either be methylated or 
acetylated and there are three different possibilities for each methylated 
site (mono, di or tri). Therefore, histone proteins may undergo an 
extremely large number of possible combinations of modifications. 
The post-translational modification state of chromatin is the result of the 
balanced activity of several enzymes. For instance, the acetylation state of 
histones is the result of the activity of acetyltransferases and 
deacetylases. 
From the functional point of view, acetylation of histone 3 and histone 4 
(H3 and H4) are associated with active transcription and commonly 
referred as euchromatin modifications. This is most likely due to the fact 
that acetylation loosens inter- or intra-nucleosomal DNA-histone 
interactions and, at the same time, affects recognition and protein-protein 
interactions. On the other side, evidences suggest that methylation of H3 
lysine 9 (H3-K9) is a mark for transcriptionally silent chromatin 189. This 
modification can be catalyzed by specific enzymes among which histone 
methyl transferase G9a, which is localized exclusively in euchromatic 
regions 190. 
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Type of 
modification 
Class of enzymes Enzymes Substrates 
acetylation acetyltransferase HAT1 H4 (K5, K12) 
  GCN5, PCAF H3 (K9, K14, 
K18) 
  CBP, P300 H3 (K14, 
K18), H4 (K5, 
K8), H2AK5, 
H2B (K12, 
K15) 
  TIP60/PLIP H4 (K5, K8, 
K12, K16), 
H3K14 
  HBO1 H4 (K5, K8, 
K12) 
 deacetylases SirT2-3 H4K16 
Lysine 
methylation 
Lysine methyl 
transferases 
SUV39H1-2; 
G9a:EuHMTase/GLP; 
ESET/SETDB1: CLL8 
H3K9 
  MLL1-5; SET1A-B; 
ASH1 
H3K4 
  SET2; NSD1;  
SYMD2 
H3K36 
  DOT1 H3K79 
  Pr-SET7/8 H4K20 
 Lysine 
demethylases 
LSD1/BHC110 H3 (K4, K9) 
  JHDM1a-b H3K36 
  JHDM2a-b H3K9 
  JMJD2A/JHDM3A, 
JMJD2B-C 
H3 (K9,K36) 
  JMJD2D H3K9 
  JARID1A-D H3K4 
  UTX; JMJD3 H3K27 
Arginine 
methylation 
Arginine methyl 
transferases 
CARM1 H3 (R2, R17, 
R26) 
  PRMT4 H4R3 
  PRMT5 H3R8, H4R3 
Phosphorylation Serine/threonine 
kinases 
Haspin H3T3 
  MSK1-2 H3S28 
  CKII H4S1 
  Mst1 H2BS14 
  Rsk2 H3S10 
Ubiquitination E3 ligases Bmi/Ring1a H2AK119 
  RNF20/RNF40 H2BK120 
 
Table 1. Histone-modifying enzymes. Human enzymes and the 
corresponding substrates (histone protein and amino acid residue) are 
listed. (M_Tablecaption). 
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Histone deacetylases 
 
Addition of acetyl groups is one of the most widespread modifications of 
histones. Acetylation at ε-amino groups of lysine residues at histone tails 
neutralizes their positive charges, thereby relaxing chromatin structure. 
Furthermore, acetylated histones also serve as binding sites for 
bromodomain proteins, often acting as transcriptional coactivators. As 
shown in table 1, histone acetylation occurs at multiple lysine residues; it 
is usually carried out by a variety of histone acetyltransferase complexes 
(HATs) and is reversed through the action of histone deacetylases 
(HDACs) 186,191.  
HDACs do not bind DNA directly, in contrast, through the interaction with 
transcriptional activators and coactivators, are recruited at target genes 
and are assembled in large multiprotein transcriptional complexes. Thus, 
the specific contribution of HDACs to the regulation of gene transcription 
depends on the cell type and on the availability of interacting proteins. 
HDACs represent a large superfamily of proteins whose members are 
grouped in different classes (Table 2) 192. Class I HDACs are ubiquitously 
expressed and found predominantly in the nuclear compartment. They 
bear a conserved deacetylase domain and are active on histone 
substrates. The catalytic domain consists of a narrow, tube-like pocket, at 
the bottom of which a zinc cation is positioned. In cooperation with two 
His-Asp charge relay systems, the zinc cation facilitates the deacetylation 
reaction. 
Class IIa HDACs carry a large N-terminal with conserved binding sites for 
the transcription factor myocyte enhancer factor 2 (MEF2) and the 
chaperone protein 14-3-3. First of all, upon  phosphorylation by means of 
different kinases, the calcium/calmodulin-dependent protein kinase and 
protein kinase D, class IIa HDACs bind 14-3-3 and translocate from the 
cytoplasm to the nucleus 193-196. When interacting with class IIa HDACs, 
MEF2 acts as transcriptional repressor; in contrast, its dissociation from 
HDACs promotes the recruitment of the histone acetyltransferase p300 
and the conversion of MEF in a transcriptional activator 197-201. Class IIa 
HDACs possess only minimal histone deacetylase activity, a behavior that 
can be explained with the fact that a key tyrosine residue in the catalytic 
domain is substituted with a histidine in class IIa HDACs 202. It should be 
emphasized that the deacetylase activity associated to cell-derived class 
IIa HDACs is due to the copurification of class I HDACs 203. At this regard 
it was shown that HDAC4 (class IIa) recruits preexisting enzimatically 
active complexes containing HDAC3 (class I) and nuclear co-repressors 
(NCo-R and SMRT), and that these protein-protein interactions are crucial 
in the transcriptional repression mechanisms involving histone 
deacetylation 203. These evidences suggest that class II HDACs behave as 
bridging molecules with little enzymatic activity, however at present it 
cannot be excluded that these enzymes act on other still unknown 
substrates. 
The most characterized member of class IIb HDACs is HDAC6, a 
cytoplasmic protein that acts on non-histone substrates such as 
cytoskeletal proteinsebbene  and transmembrane proteins 192. 
Finally, HDAC11 is the only member of class IV whose functions are still 
elusive 192. 
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Class Protein domains Members 
Class I Deacetylase catalytic domain 
Phosphorylation sites (serine residues) at C 
terminus 
 
HDAC1 
HDAC2 
HDAC3 
HDAC8 
Class IIa Deacetylase catalytic domain 
Phosphorylation sites (serine residues) at N 
terminus 
Myocyte enhancer factor binding sites 
Binding sites for 14-3-3 chaperone protein 
HDAC4 
HDAC5 
HDAC7 
HDAC9 
Class IIb Deacetylase catalytic domain 
Zinc finger domain or Leucine rich region 
HDAC6 
HDAC10 
Class IV Deacetylase catalytic domain HDAC11 
 
Table 2. The mammalian histone deacetylase superfamily. The list does 
not incluce class III HDACs, a term sometimes used to indicate sirtuins, a 
distinct group of deacetylases. (M_Tablecaption). 
 
 
Histone Deacetylase Inhibitors 
 
From the structural point of view, synthetic HDAC inhibitors can be 
classified in four groups: short-chain fatty acids, hydroxamic acids, 
benzamide derivatives, and cyclic peptides. We will briefly highlight the 
main features of each class addressing interested readers to specific 
reviews on the topic204. 
Short-chain fatty acids such as sodium butyrate, sodium phenylacetate, 
phenylbutyrate and valproate, are active at millimolar concentrations and 
can be defined pan-inhibitors although they seem to be less active against 
class IIb HDACs. The mechanism by which this class of compounds 
inhibits HDACs has not been fully elucidated. 
The first compound bearing a hydroxamic acid moiety to be described as 
HDAC inhibitor was trichostatin A (TSA), which is produced by 
Streptomyces hygroscopicus and displays antifungal activities. However, 
the prototype compound of this class is suberoylanilide hydroxamic acid 
(SAHA) that was approved by the US FDA in 2006 for cutaneous 
manifestations of cutaneous T-cell lymphoma. Hydroxamic acids are 
usually active in the nanomolar range and inhibit HDACs by complexing 
the zinc cation present in the catalytic pocket of the enzyme with the 
hydroxamate group. 
The cyclic peptide romidepsin (formerly known as FK-228) is produced by 
Chromobacterium violaceum and shows higher inhibitory activity toward 
class I HDACs, with IC50 in the nanomolar range. In the cellular reducing 
environment, this compound is converted into its reduced form that can 
interact with the enzyme active site. This molecule was very recently 
approved by US FDA for patients with cutaneous T-cell lymphoma. 
Finally, MS-275 is the lead compound of the benzamide derivatives series. 
This compound is highly active against class I HDACs and almost 
completely inactive toward class II enzymes. 
In addition, several natural compounds have been added to the list of 
HDAC inhibitors in the last years. The beneficial effects of dietary 
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isothiocyanates and allyl sulfides on human health, and in particular their 
cancer chemopreventive effects, have been known for a long time205 
however, only recently their positive actions have been linked with 
epigenetic mechanism.  
A major understanding of HDAC active site structure and of the molecular 
features required to inhibit HDAC catalytic activity, in particular the 
presence of a spacer “arm” that allows the entry into the catalytic pocket 
and of a functional group interacting with the zinc cation, led to the 
reconsideration of the biological activity of several natural compounds.  
Sulforaphane (SFN) is one of the most characterized isothiocyanates 
found in vegetables. It derives from the glucosinolate glucoraphanin 
present in cruciferous vegetables, such as broccoli and broccoli sprouts. 
Like other isothiocyanates, it is metabolized via the mercapturic acid 
pathway to active metabolites, among which SFN-cysteine displays a good 
fit for HDAC active site according to computer modeling predictions206. 
Indeed, the effects of SFN in vitro and in vivo systems are associated with 
increased global histone acetylation207-209. 
Allyl compounds are garlic components comprising diallyl disulfide and S-
allyl mercaptocysteine, which are both converted into the active 
metabolite allyl mercaptane. Docking simulation revealed a good fit 
between allyl mercaptane and HDAC active site, consistent with 
accumulation of acetylated histones and growth arrest in cancer cells 
treated with the active metabolite at micromolar concentrations210. 
Finally, sodium butyrate that we mentioned before as a synthetic HDAC 
inhibitor, should also be included in the list of naturally occurring 
inhibitors since it is generated during the fermentation of dietary fibers in 
the large intestine211. 
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Effects of Histone Deacetylase Inhibitors on Energy Metabolism 
 
A recent study provided further evidence supporting the involvement of 
HDACs in energy expenditure. In fact, Gao et al. reported that sodium 
butyrate, a dietary component found in cheese and butter and also 
produced in the large intestine after fermentation of dietary fibers, 
improves metabolic dysfunction in mice fed a high-fat diet212. In 
particular, supplementation with sodium butyrate prevents diet-induced 
obesity, increase energy expenditure, and improves insulin sensitivity. 
These metabolic changes reflect beneficial effects of sodium butyrate on 
brown adipose tissue and skeletal muscle since treated mice show 
increased adaptive thermogenesis, and a higher number of oxidative 
fibers, coupled with enhanced fatty acid oxidation and mitochondrial 
function, in skeletal muscles. 
 
 
Beyond Histones  
 
As briefly mentioned above, histones are not the only proteins whose 
biological activities are modulated by the acetylation state at lysine 
residues213. In particular, acetyltransferases themselves such as the 
transcriptional coactivators p300 and CBP are heavily acetylated. 
Acetylation at lysine residues occurs also at the level of other transcription 
factors and cofactors such as the tumor suppressor p53; nuclear factor 
κB; members of the O group of the forkhead-box transcription factors; 
nuclear hormone receptors including androgen, progesterone, estrogen, 
and liver X receptors; PGC-1α, and receptor interacting protein 140. 
In addition, also cytoplasmic proteins present acetylation sites. This is the 
case for example of metabolic enzymes (acetyl-CoA synthase, glutamate 
dehydrogenase), of α-tubulin, and heat shock protein 90. 
 
 
Sirtuins, Transcriptional Coactivators, and Mitochondria 
 
Sirtuins were initially discovered as silencing factors and longevity-linked 
proteins in lower organisms. The discovery that they act as NAD+-
dependent histone deacetylases214 represented a significant breakthrough 
that allowed to appreciate the multiple roles played by these enzymes in 
patho-physiology. Besides histones, sirtuins act on a variety of acetylated 
substrates with different functions. SIRT1 deacetylates transcription 
factors and coactivators such as p53, nuclear factor κB, proteins belonging 
to the forkhead box type O (FOXO) family, PPARγ, PGC-1α; but it also acts 
on enzymes such as acetyl-CoA synthases, or on structural proteins such 
as α-tubulin215. 
In mammals, sirtuins regulate a variety of functions, from the control of 
cellular stress to energy metabolism216. The first indication that sirtuins, in 
particular SIRT1, is involved in the metabolic control in mammals came 
from the elegant studies of P. Puigserver and coworkers who were 
investigating the molecular mechanisms responsible for the adaptive 
metabolic response to fasting. Reduced availability of nutrients, such as 
that experienced in fasting and calorie restriction, is reflected at the 
cellular level by a decrease of oxidative pathways and, consequently, by 
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an increase of NAD+/NADH ratio. Rodgers et al. found that in the fasted 
state SIRT1 is induced in the liver and deacetylates PGC-1α at specific 
lysine residues in an NAD+-dependent manner217. Deacetylated PGC-1α 
more actively transactivates the transcription of target genes, particularly 
those involved in gluconeogenesis217. In line with these observations, the 
knock-down of SIRT1 in the liver leads to reduced glucose production and 
fatty acid oxidation in the liver, under the fasting condition218. These 
metabolic changes are linked to decreased expression of genes 
responsible for gluconeogenesis and fatty acid oxidation218. These studies 
clearly demonstrate that SIRT1 is a key regulator of metabolic adaptation 
to nutrient deprivation and that PGC-1α mediates most of SIRT1 effects.  
 
Effects of SIRT Activators on Energy Metabolism 
 
In 2003 Howitz et al. reported for the first time that small molecules such 
as the natural polyphenol resveratrol, can extend the lifespan of S. 
cerevisiae in a Sir2-dependent manner219.  
Subsequent studies in animal models of insulin resistance and high-calorie 
diet showed that resveratrol administration ameliorates the metabolic 
derangements observed in these mice119,220. In particular, resveratrol 
attenuates adipogenesis and fat storage in white adipose tissue and, at 
the same time, improves mitochondrial activity and thermogenesis of 
brown adipose tissue. Resveratrol also affects insulin and glucose 
homeostasis since it increases insulin secretion from the pancreas and 
improves insulin sensitivity in the skeletal muscle, accompanied by 
enhanced mitochondrial activity and fatty acid oxidation. These metabolic 
effects are associated to activation of AMP-activated kinase and PGC-1α. 
In particular, this latter effect is due to SIRT1-dependent deacetylation119. 
Indeed, all these factors are strictly and coordinately linked. In fact, AMP-
kinase, a sensor of the cellular energy status that is activated by a rise of 
AMP/ATP ratio, increases SIRT1 activity by increasing NAD+ cellular levels 
and consequently causing deacetylation of PGC-1α and FOXO transcription 
factors221. 
Although the animal studies discussed above clearly indicated that the 
effects of resveratrol are SIRT1-dependent, the observation that this 
polyphenol also activates AMP-kinase, makes difficult to establish which is 
the primary target of resveratrol. In fact, resveratrol increases SIRT1 
deacetylating activity toward synthetic substrates containing a fluorescent 
moiety but appears to have no direct effect on physiological 
substrates222,223.
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Type 2 diabetes mellitus (T2DM) is the most common metabolic disease in 
the world. The westernization of the diet and sedentary lifestyle are the 
most responsible factors that drive to insulin resistance and T2DM. 
Maintenance of glucose homeostasis depends on a complex interplay 
between the insulin responsiveness of skeletal muscle, liver, adipose 
tissue and glucose-stimulated insulin secretion by pancreatic beta cells. 
Defects in these organs are responsible for insulin resistance and 
progression to hyperglycemia. 
Understanding the integrated pathophysiology initiating the development 
of insulin resistance should extend our capacity to identify novel 
therapeutic targets for the prevention and/or treatment of T2DM. This 
biology remains incompletely characterized, in part, due to the interaction 
of multiple organ systems and numerous intracellular perturbations within 
these organs (including disrupted signaling and metabolic alterations) 
governing the development of insulin resistance. The complexity of this 
biology is further underscored by the progressive changes in the systemic 
milieu including the onset of hyperinsulinemia, elevated circulating free 
fatty acids and triglycerides, hyperglycemia, and the activation of 
systemic immune system during the development of T2DM. 
Skeletal muscle is integral to the development of insulin resistance and is 
a major reservoir for postprandial glucose storage. In skeletal muscle, loss 
of mitochondrial function is evident in some insulin-resistant subjects 
years before they develop diabetes. Mitochondria are particularly 
important for skeletal muscle function, given the high oxidative demands 
imposed on this tissue by intermittent contraction, in fact they ensure 
adequate levels of ATP needed for contraction by the muscle sarcomere. 
Moreover, muscle cells must maintain metabolic flexibility, defined as the 
ability to rapidly modulate substrate oxidation as a function of hormonal 
and energetic conditions. 
The molecular mechanisms that control mitochondrial number and 
function remain poorly understood, and only a few transcription factors or 
coactivators (e.g., PGC-1α, NRF1, Tfam) have been associated with this 
process. Notably, skeletal muscle differentiation and remodelling are also 
controlled at the epigenetic level, via transcriptional modulation of key 
genes in mitochondrial biogenesis and oxidative metabolism, involving 
enzymes, such as members of the histone deacetylase (HDAC) family, in 
particular those belonging to class I and class II, which modulate post-
translational modifications on target proteins. The current knowledge on 
HDACs is that they function in general as transcriptional repressors, 
however their role in vivo is likely more complex. Sirtuins (SIRT), 
members of class III HDACs, represent an example of this complexity 
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since they may act either as activators of gene transcription by increasing 
the PGC-1α coactivating activity, or as transcriptional repressors by 
targeting p53. A number of recent studies have demonstrated that direct 
or indirect sirtuin activators promote mitochondrial function in vivo 
ameliorating the metabolic profile in animal models of insulin 
resistance/diabetes119,215,221. 
Less is known on the effects of HDACs modulators on energy metabolism, 
however a recent study reported that supplementation with sodium 
butyrate, a dietary component active as HDAC inhibitor, promotes energy 
expenditure and mitochondrial function in mice fed with a high fat diet212. 
Given the importance of skeletal muscle metabolism in insulin 
resistance/diabetes, and given the role of HDACs in skeletal muscle 
biology, it is reasonable to speculate that modulation of these enzymes 
would play a role in this pathology that deserves to be investigated more 
deeply. 
Based on the evidences that mitochondrial dysfunction is often associated 
to whole body metabolic dysregulation, aim of this study is to better 
understand the role of histone deacetylases in the regulation of 
mitochondrial biogenesis and in the modulation of all these mechanisms 
underlying the pathophisiology of insulin resistance. 
To this end we treated a cellular model of skeletal muscle (C2C12 cell 
line) with pan- and class selective HDAC inhibitors (HDACi), in particular 
with SAHA (pan-inhibitor), MS275 (Class I HDAC inhibitor) and MC1568 
(Class II HDAC inhibitor), to evaluate the effects of these compounds on 
mitochondrial density, activity and on the whole transcriptome. 
Moreover, the in vivo study has been performed in a genetic model of 
insulin resistance (Db/Db mice) to characterize the effects of the 
biochemical inhibition of HDACs in the main tissues involved in the 
homeostasis of energy metabolism, such as skeletal muscle, white and 
brown adipose tissues and liver. 
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Reagents and Plasmids 
 
Valproic Acid (VPA) and Trichostatin A (TSA) were from Sigma Aldrich 
(Milano, Italy), Suberoyl anilide hydroxamic acid (SAHA) were from 
Cayman Chemical (Ann Arbor, MI). MS275, MC1568 were sinthetized by 
the laboratory of Prof. Antonello Mai (Roma, Italy). 8Br-cAMP and KT5720 
were from Sgma Aldrich (Milano, Italy). 
MitoTracker Green FM and MitoTracker Red CM-H2XRos were from 
Molecular Probes, Invitrogen (Carlsbad, CA), Hoechst 33258 were from 
Sigma Aldrich (Milano, Italy). The primary antibody anti Acetyl-H3, anti 
CREB, anti Phospho-CREB, the secondary antibody anti rabbit IgG were 
from Cell Signaling Technology (Danvers, MA). The primary antibody anti 
Acetyl Tubulin, anti alpha tubulin, anti beta actin and the secondary 
antibody anti mouse IgG were from Sigma Aldrich (Milano, Italy). 
The plasmid pTKmTFALuc was provided by Dr. Enrique Saez (The Scripps 
Research Institute, La Jolla, CA). 
The plasmids PGC-1 alpha promoter 2kb luciferase (Addgene plasmid 
8887) and PGC-1 alpha promoter luciferase delta CRE (Addgene plasmid 
8888) were from Addgene (Cambridge, MA). 
The plasmid pCDNA3HDAC1 was provided by Dr. Eric Olson (University of 
Texas Southwestern Medical Center, Dallas, TX). 
 
 
Cell cultures and transfections 
 
C2C12 myoblast 
C2C12 myoblast are a subclone (produced by H. Blau, et al) of the mouse 
myoblast cell line established by D. Yaffe and O. Saxel. 
The C2C12 cell line differentiates rapidly, forming contractile myotubes 
and producing characteristic muscle proteins. Treatment with bone 
morphogenic protein 2 (BMP-2) cause a shift in the differentiation 
pathway from myoblastic to osteoblastic. 
Manteinance medium: Dulbecco's Modified Eagle's Medium. To make the 
complete growth medium, add fetal bovine serum to a final concentration 
of 10%, L-Glutamine and Pen/Strep. 
Differentiation medium: Dulbecco's Modified Eagle's Medium. To make the 
complete growth medium, add horse serum to a final concentration of 
2%, L-Glutamine and Pen/Strep. 
Temperature: 37.0°C 
Subculturing protocol: 
Cultures must not be allowed to become confluent as this will deplete the 
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myoblastic population in the culture.  
1. Remove and discard culture medium. 
2. Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA 
solution to remove all traces of serum which contains trypsin inhibitor. 
3. Add 3.0 ml of Trypsin-EDTA solution to flask and observe cells under 
an inverted microscope until cell layer is dispersed (usually within 5-7 
minutes). 
Note: To avoid clumping do not agitate the cells by hitting or shaking the 
flask while waiting for the cells to detach. Cells that are difficult to detach 
may be placed at 37°C to facilitate dispersal. 
4. Add 7.0 ml of complete growth medium and aspirate cells by gently 
pipetting. 
5. Add appropriate aliquots of the cell suspension to new culture 
vessels. 
Inoculate at a cell concentration between 1.5 X 10 exp5 and 1.0 X 10 
exp6 viable cells/75 cm2. 
6. Incubate cultures at 37°C. 
Medium Renewal: Every two days. 
Differentiation protocol: 
Plate cells at the final concentration of 70000 cells/ml in 24-, 12- or 6-well 
plates. Two days after plating, cells become confluent. Switch the medium 
with the differentiation medium and renew it every two days for 4 days. 
At the fifth day cells are completely differentiated. 
 
Transfection protocol: 
Prepare the mix DNA/Lipofectamine 2000 ratio 1:2.5 (200ng of total DNA 
per well) in DMEM medium without serum and antibiotics. Mix formation 
time: 30 min. 
Meantime split the cells and use 8000 cells/ well. 
Prepare a mix with culture media, the cells and add to this mix the 
DNA/Lipofectamine2000 mix (usually the DNA/cells mix is 1/10 of the 
total volume of the mix with cells). Incubate cells with the 
DNA/Lipofectamine mix up to 45 min. Plate the cells with DNA mix and 
after an overnight remove the medium a treat the cells.  
C2C12 cells were treated with VPA 5mM, TSA 50nM, SAHA 5µM, MS275 
5µM, MC1568 5µM, 8Br-cAMP 1mM or KT5720for different times. 
Cells were lysed using briteliteTM plus (Perkin Elmer, Monza, Italy) and 
RLU were detected with EnVision (Perkin Elmer Waltham, MA). 
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Generation of clones stably transfected: 
Cells were transfected as above descripted. The following day, media were 
replaced with media containing G418 in order to select cells that have 
stably incorporated the plasmid into their genomic DNA. The media were 
renew every two days for 15 days increasing G418  concentration to avoid 
the generation of resistant cells and splitting them when needed.  
 
 
Real Time quantitative RT-PCR 
 
Total RNA from C2C12 myotubes was double extracted with TRIzol 
Reagent® (Invitrogen) and purified with commercial kit (Macherey-Nagel, 
Milano, Italia) and quantitated with Nanodrop (Thermo Scientific, 
Wilmington, DE). Specific mRNA was amplified and quantitated by real 
time PCR, using Sybr Green kit (Bio-Rad, Milano, Italia) as previously 
described (De Fabiani et al., 2003) or iScriptTM One Step RT-PCR for 
Probes (Bio-Rad, Milano, Italia), following the manufacturer’s instructions. 
Primer sequences are available on request. Data were normalized to 18S 
rRNA or 36B4 mRNA and quantitated setting up  a standard curve. 
We monitored the specificity of the amplified products by melting curve 
analysis, when PCR was run with SybrGreen kit. Experiments were 
performed in triplicate and repeated at least twice with different cell 
preparations. Primers for real-time PCRs were designed with Primer 
Express software (Applied Biosystems, Monza-Milan, Italy) or IDT 
software avilable on line and optimized to work in a two-step protocol (40 
cycles of amplifications each consisting of a denaturation step at 95° C for 
15 s and an annealing/extension step at 60° C for 60 s) or one-step 
protocol (10 min at 50°C for reverse transcription, 40 cycles of 
amplifications each consisting of a denaturation step at 95° C for 10 s and 
an annealing/extension step at 60° C for 30 s). The oligonucleotides used 
for real-time PCR were synthesized by Primm (Milano, Italy) or Eurofin 
MWG Operon (Ebersberg, Germany). 
For mitochondrial DNA cotent QPCR was performed on 12S mtDNA 
sequence and cyp7a1 promoter DNA sequence.  
 
 
Immunocytochemistry 
 
C2C12 cells were cultured in 4-well plate. After incubation with the 
compounds at the appropriate concentration, cells were stained with 
MitoTracker Green 200 nM and MitoTracker Red CM-H2Xros 400 nM. Cells 
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were incubated for 30 minutes at 37°C. After incubation dyes were 
removed and cells were washed three times with PBS. After that, cells 
were incubated 30 seconds with Hoechst 33258 in order to  mark the 
nuclei, washed three times with PBS and pictures were taken using a 
fluorescence microscope Axiovert 200 (Zeiss). 
 
 
Mitochondrial density and activity 
 
C2C12 cells were cultured in 96-well plate. After incubation with the 
compounds at the appropriate concentration, cells were stained with 
MitoTracker Green and MitoTracker Red CM-H2Xros as described above. 
Cells were incubated for 30 minutes at 37°C. After incubation with 
Hoechst 33258, cells were washed three times with PBS and fluorescence 
intensity were measured using EnVision (Perkin Elmer, Waltham, MA). 
 
 
Protein extraction and Western Blot analysis 
 
C2C12 myotubes were lysed using SDS sample buffer (62.5 mM Tris- HCl 
pH 6.8, 2% w/v SDS, 10% glycerol, 50 mM DTT, 0.01% w/v bromophenol 
blue or phenol red). 
A. Solutions and Reagents 
Transfer Buffer: 25 mM Tris base, 0.2 M glycine, 20% methanol (pH 8.5). 
10X Tris Buffered Saline (TBS): To prepare 1 liter of 10X TBS: 24.2 g Tris 
base, 80 g NaCl; adjust pH to 7.6 with HCl (use at 1X). 
Blocking Buffer: 1X TBS, 0.1% Tween-20 with 5% w/v nonfat dry milk; 
for 150 ml, add 15 ml 10X TBS to 135 ml water, mix. Add 7.5 g nonfat 
dry milk and mix well. While stirring, add 0.15 ml Tween-20 (100%). 
Wash Buffer: 1X TBS, 0.1% Tween-20 (TBS/T). 
Primary Antibody Dilution Buffer: 1X TBS, 0.1% Tween-20 with 5% nonfat 
dry milk as indicated on primary antibody datasheet 
B. Protein Blotting 
Lyse cells by adding 1X SDS sample buffer (100 µl per well of 6-well 
plate). Immediately scrape the cells off the plate and transfer the extract 
to a microcentrifuge tube. Keep on ice. 
Sonicate for 10–15 seconds for complete cell lysis and to shear DNA (to 
reduce sample viscosity). 
Microcentrifuge for 5 minutes. 
Load 20 µl onto SDS-PAGE gel (10 cm x 10 cm).  
Electrotransfer to nitrocellulose membrane. 
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C. Membrane Blocking and Antibody Incubations 
I. Membrane Blocking 
Incubate membrane in 25 ml of blocking buffer for one hour at room 
temperature. 
Wash three times for 5 minutes each with 15 ml of TBS/T. 
II. Primary Antibody Incubation 
Proceed to one of the following specific set of steps depending on the 
primary antibody used. 
Incubate membrane and primary antibody (at the appropriate dilution as 
recommended in the product datasheet) in 10 ml primary antibody 
dilution buffer with gentle agitation overnight at 4°C. 
Wash three times for 5 minutes each with 15 ml of TBS/T. 
Incubate membrane with the species appropriate HRP-conjugated 
secondary antibody for 1h at room Temperature with gentle agitation. 
Wash three times for 5 minutes each with 15 ml of TBS/T. 
D. Detection of Proteins 
Incubate membrane with appropriate volume of SuperSignal West Pico 
Chemiluminescent Substrate (Pierce Thermo Scientific) for 5 minutes. 
Drain membrane of excess developing solution (do not let dry), wrap in 
plastic wrap and expose to x-ray film.  
 
Antibody dilutions used for western blot: 
1. Anti Acetyl Histon H3: 1:1000 
2. Anti Acetyl Tubulin: 1:1000 
3. Anti Tubulin: 1:1000 
4. Anti beta-actin: 1:2000 
 
5. Anti rabbit IgG: 1:5000 
6. Anti mouse IgG: 1:5000 
 
 
Microarray analysis 
 
Microarray analysis were performed by Genopolis.Arrays and conditions 
used in the experiments are reported in Tables 1-6. Data handling was 
mainly done using Bioconductor 2.4. The Robust Multichip Average (RMA) 
method was employed to calculate probe set intensity. RMA is a robust 
multi-chip average expression method that estimates the probe-level data 
from a set of chips: the perfect-match (PM) values are background-
corrected, normalized and finally summarized resulting in a set of 
expression measures. To filter out noisy data before the selection of 
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differentially expressed genes a filter is applied based on a Inter Quantile 
Range (IQR). The identification of differentially expressed genes was 
addressed using Linear Models for Mi- croarray Data (LIMMA). The 
identification of differentially expressed genes (DEGs) was addressed 
using linear modeling approach and empirical Bayes methods together 
with false discovery rate correction of the p-value (Benjamini-Hochberg).  
 
 
Table 1 
 
Title C2C12 project 
Date January 11, 2010 
Chip mogene10sttranscriptcluster.db 
Samples number 15 
Condition number 5 
Normalization Method RMA 
Prefiltering Method IQR 
Filtered Probesets 17168 
Remaining Probesets 18344 
DEG Selection Method Limma 
DEG Selection Threshold 0.001 
Experimental Design commonBaseline 
Total DEG number 2355 
 
Table 2 
Title Gastrocnemius 
Date April 14, 2010 
Chip mogene10sttranscriptcluster.db 
Samples number 12 
Condition number 3 
Normalization Method RMA 
Prefiltering Method IQR 
Filtered Probesets 9380 
Remaining Probesets 19435 
DEG Selection Method Limma 
DEG Selection Threshold 0.01 
Experimental Design commonBaseline 
Total DEG number 2778 
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Table 3 
Title Vastus Lateralis 
Date April 8, 2010 
Chip mogene10sttranscriptcluster.db 
Samples number 12 
Condition number 3 
Normalization Method RMA 
Prefiltering Method IQR 
Filtered Probesets 10757 
Remaining Probesets 18058 
DEG Selection Method Limma 
DEG Selection Threshold 0.01 
Experimental Design commonBaseline 
Total DEG number 2624 
 
Table 4 
Title Liver 
Date April 15, 2010 
Chip mogene10sttranscriptcluster.db 
Samples number 12 
Condition number 3 
Normalization Method RMA 
Prefiltering Method IQR 
Filtered Probesets 9096 
Remaining Probesets 19719 
DEG Selection Method Limma 
DEG Selection Threshold 0.05 
Experimental Design commonBaseline 
Total DEG number 911 
 
Table 5 
Title BAT 
Date July 19, 2010 
Chip mogene10sttranscriptcluster.db 
Number of Samples 12 
Number of Conditions 3 
Normalization Method RMA 
Prefiltering Method IQR 
Filtered Probesets 9657 
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Remaining Probesets 19158 
DEG Selection Method Limma 
DEG Selection Threshold 0.005 
FoldChange Threshold 1 
Experimental Design commonBaseline 
Total number of DEGs 1057 
 
Table 6 
Title WAT 
Date July 22, 2010 
Chip mogene10sttranscriptcluster.db 
Number of Samples 9 
Number of Conditions 3 
Normalization Method RMA 
Prefiltering Method IQR 
Filtered Probesets 1016 
Remaining Probesets 27799 
DEG Selection Method Limma 
DEG Selection Threshold 0.03 
FoldChange Threshold 1 
Experimental Design commonBaseline 
Total number of DEGs 1024 
 
Table 1-6: conditions used for microarray analysis in C2C12 myotubes, 
gastrocnemius, vastus lateralis, liver, brown adipose tissue and white 
adipose tissue of Db/Db mice. 
 
 
Animal Studies 
 
C57BLKS/J-Leprdb/db mice were purchased from The Jackson Laboratory. 
Nine-week-old male db/db mice were randomized into four groups 
according to glucose levels and body weight and treated with 
intraperitoneal (i.p.) injection of SAHA (25mpk), MS275 (10mpk), MC1568 
(6.5 mpk) or with vehicle (DMSO) every other day. 
All the compounds were dissolved in DMSO and stored at +4°C. Prior to 
use, the solutions were warmed in a 42°C water bath with agitation. For 
blood analysis, db/db mice were fasted for 16 hr and blood was collected 
from the tail vein. Glucose levels were determined using an Accu-Chek 
Active glucometer (Roche). Triglyceride levels were determined by the 
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Plasma Triglyceride Kit (Sentinel). Free fatty acid levels were determined 
by the NEFA-HR kit (Wako). Insulin levels were determined using an 
AlphaLISA® Human Insulin Research Immunoassay Kit (Perkin Elmer). 
Cholesterol levels were determined using ABX Diagnostic Cholesterol kit 
(ABX Pentra). Cholesterol distribution in plasma lipoprotein fractions was 
determined by FPLC using a Superose 6 column (Amersham, Milano, 
Italia). One-ml fractions were collected and assayed for cholesterol using 
an enzymatic kit (ABX Pentra)and triglycerides (Sentinel). ALT and AST 
levels were determined using ALT or AST Reagent Set (Teco Diagnostic). 
For glucose tolerance tests, mice were fasted for 16 hr, and glucose levels 
from tail-vein blood were determined before and 30, 60, 90, and 120 min 
after i.p. injection of glucose (2 g/kg). For insulin tolerance tests, random 
fed mice were injected i.p. with insulin (Humulin R, Eli Lilly) (2 U/kg). 
Glucose levels were determined before and 30, 60, 120, 180, and 210 min 
after injection. At the end of treatments, gastrocnemius, vastus lateralis, 
soleus, brown and white fat, liver and blood samples were collected from 
individual animals. 
Animal studies were conducted strictly following regulations of European 
Community (EEC Directive n. 609/86) and local regulations for animal 
care (Italian Legislative Decree n. 116, 27/01/1992). 
 
 
Indirect Calorimetry 
 
Oxygen consumption, heat production, and activity were measured over 3 
days using the Oxymax Lab Animal Monitoring System (Columbus 
Instruments). Mice (five 10-week-old db/db males per group) were 
individually housed and allowed to acclimate in the experimental cages 
with free access to food and water. Animals were maintained on a 12 hr 
light/dark cycle and were treated with vehicle or compounds for 15 days 
prior to the start of the experiment. During the experiment, mice were 
dosed as described above. Data was analyzed using the OxymaxWin 
v3.32 software package. Statistical comparisons of repeated 
measurements were made using ANOVA.  
 
 
Histological Analysis 
 
Muscle 
8 µm thick sections from gastrocnemius muscle of treated mice, 
embedded in paraffin, were deparaffinized with xylene and rehydrated 
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through graded ethanol and stained using the following protocols: 
 
SUCCINATE DEHYDROGENASE 
1. Phosphate buffer (100mM, pH 7.6) 
Solution A (1.36g KH2PO4 /100ml) 12ml 
Solution B (1.42g Na2HPO4/100ml) 88ml 
2. NBT Stock 
Phosphate buffer as above 100ml 
KCN 6.5mg 
EDTA 185mg 
Nitroblue tetrazolium (NBT) 100mg 
3. Succinate stock (500 mM sodium succinate) 
Sodium succinate 2.7g 
Distilled water 20ml 
Freeze in 5ml amounts 
4. Incubation medium 
NBT stock 2.0ml 
Succinate stock 0.2ml 
Phenazine methosulphate 0.7mg (one small crystal) 
Mix just before use, keep out of strong light. 
 
Incubation for 30 minutes at 37°C 
Wash in distilled water, clear and mount. 
 
GOMORI TRICHROME 
 
Harris’s Hematoxylin for 10 min  
Wash for 10 min  
Gomori Trichrome for 10 min   
Wash in acetic acid 0,2 % twice  
Dehydrate, clear and mount in Biomount. 
 
PAS 
Reagents: 
Carnoy fixative  
Periodic acid acqueous solution 0.5 % 
Schiff reactive 
Sodium metabisulfite 0.5 % 
 
Protocol: 
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Put slices in Carnoy fixative at 4°C for 5 min 
Rinse Carny fixative and incubate in periodic acid 0.5% for 10 min 
Put slices in Schiff reactive, protect from light for 20 min    
Wash in sodium metabisulfite 0.5 % for 10 min 
Wash in distilled water rapidly 
Counterstain in Mayer’s hematoxylin for 5 min 
Wash in water for 5 min 
Dehydrate, clear and mount. 
 
ESTERASE 
Reagentis 
Phosphate buffer 0.2 M pH 7.27 
a-naphthyl acetate 1% in acetone  
pararosaniline stock solution 
Sodium notrite 4% in H20 
 
Solutions: 
pararosaniline stock solution: 
Pararosaniline   4 g 
Distilled Water   80 ml 
HCl     20 ml  
Warm the solution gently shaking. 
Cool, filter and store for 15 days at RT 
 
Incubation solution: 
Phosphate buffer 0.2 M pH 7.27  10 ml 
a-naphthyl acetate 1%    10 drops 
Pararosaniline stock solution   9 drops  
Sodium nitrite 4 %     8 drops 
Mix first  pararosaniline and sodium nitrite, shake and add all the other 
reagents. 
 
Protocol: 
Incubation in Esterase solution at 37 °C for 1 hour 
Wash in H2O for 10 min. 
Dehydrate starting from alcohol 90% 
Clear and mount. 
 
ALCALINE PHOSPHATASE: 
Reagents: 
Boric acid  
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Borax 
Water 
a-naphthyl phosphate 
Fast blue RR 
Magnesium sulfate 0,1 M 
 
Solutions: 
 
1.Borate buffer pH 8,8 
Boric acid 0,2 M 
Borax 0,05 M 
2. Alcaline phosphatase solution pH a 8,6 
Borate buffer pH 8,8  90 ml 
a-naphtyl phosphate  150 mg 
Fast blue RR    200 mg 
 
Magnesium sulfate 0,1 M  10 ml 
 
Protocol: 
 
Incubation with Alcaline phosphatase solution at 37°C  for 1 hour 
Wash with water 3 times 
Fix with formalin 10% for 10 min. 
Wash with water for 5 min. 
Mount in glycerine.  
 
 
Immunohistochemistry 
 
White adipose tissue was fixed with Carnoy solution/Clorophorm, 
dehydrated, and embedded in paraffin, and 8 µm thick sections were 
subjected to hematoxylin-and-eosin staining. For immunohistochemistry, 
slides containing 8 µm sections were deparaffinized with xylene and 
rehydrated through graded ethanol. Antigen retrieval was performed with 
NH4Cl 0.05 M  for 30 min at RT. Endogenous peroxidase activity was 
blocked with 1% hydrogen peroxide in PBS for 20 min. Blocking step was 
performed incubating the slices in 1% BSA in PBS-Triton 0.1% for 1 hour 
at RT. Purified rat anti-mouse Mac1 antibody (AbD Serotec, Oxford, UK) 
or rabbit anti-mouse UCP1 antibody (Abcam, Cambridge, MA) was applied 
at 1:300 concentration in BSA 1% PBS overnight at 4°C. Slices were 
subsequently incubated with anti-rat (Vector Laboratories, Burlingame, 
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CA)or anti-rabbit (Perkin Elmer, Waltham, MA) biotinylated secondary 
antibodies at 1:3000 concentration. Histochemical reactions were 
performed using diaminobenzidine (DAB), and the slices were 
counterstained with hematoxylin. 
 
 
Cell size measurement 
 
Images at 20X magnification of H&E stained sections of WAT and BAT 
were analysed using Photoshop CS3  software (Palo Alto, CA), converting 
pixel number in surface dimensions and adjusted for the magnification 
factor. 
 
 
Statistical Analyses 
 
Statistical analyses were performed with Student’s t test or one-way 
ANOVA followed by Dunnett’s Post Test when needed using GraphPad 
InStat version 5.0 for Macintosh (GraphPad, San Diego, California). 
All the statisctical analysis are compared against control group, except 
where indicated. 
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HDAC inhibitors promote mitochondrial biogenesis in C2C12 
myotubes. 
 
Because histone deacetylases (HDACs) are involved in the development 
and in the physiology of skeletal muscle, we treated differentiated C2C12 
with different HDAC inhibitors and we checked their effects on 
mitochondrial biogenesis. 
First, we validated the specificity of each compound to inhibit all the 
classes of HDACs or a specific one of them. To this end, we treated C2C12 
myotubes for 24 hours with SAHA, a pan-inhibitor of HDACs, and with two 
Class selective HDAC inhibitors: MS275 (Class I selective inhibitor) and 
the MC1568 (class II selective inhibitor) and  we checked the acetylation 
status of two different targets of HDACs: the Histone H3 as Class I HDAC 
target and the α-tubulin as Class II HDAC target. 
As expected, even using different concentration of the compound, the 
treatment with SAHA increases the acetylation status of both targets, 
while the Class I selective HDAC inhibitor MS275 increases the acetylation 
status only of the Histone H3. Vice versa, the Class II HDAC selective 
inhibitor MC1568 increases only the acetyl-α-tubulin levels (fig.1). 
 
 
 
Figure 1: Acetylation levels of HDAC targets. Histone H3 is a target of 
Class I HDACs, while α-tubulin is the Class II HDAC target.  
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Once demonstrated the specificity of the different treatments on HDAC 
activity, using specific stainings for mitochondrial density and activity 
showed that only SAHA and MS275 treatments were able to increase both 
mitochondrial density and activity, while MC1568 was ineffective (fig. 2). 
 
 
 
 
Figure 2: Fluorescence microscopy showing C2C12 myotube treated for 60 
hours with vehicle, SAHA 5µM, MS275 5µM and MC1568 5µM. Cells have 
been labelled with MitoTracker Green 200 nM and MitoTracker Red CM-
H2XRos 400 nM. 
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In order to quantify the effects observed, we set up a method to measure 
fluorescence intensity in 96 well plates using Hoechst staining as relative 
paramenter to normalize the data. 
As in the case of fluorescence microscopy, we observed a significant 
increase of mitochondrial density and activity after treatment with SAHA 
and MS275, while we do not observe any differences with MC1568 (fig.3). 
 
 
 
Figure 3: Fluorescence intensity quantifications of mitochondrial density 
and activity in C2C12 treated for 60 hours with with vehicle, SAHA 5µM, 
MS275 5µM and MC1568 5µM. Cells have been labelled with MitoTracker 
Green 200 nM and MitoTracker Red CM-H2XRos 400 nM. (**p<0.01, 
***p<0.001) 
 
 
To definitely demonstrate that inhibition of Class I HDACs induces 
mitochondrial biogenesis, we measured mitochondrial DNA (mtDNA) 
content in C2C12 myotubes after HDACi treatments. Consistently with the 
previous results, we founded that SAHA and MS275 significantly increase 
mtDNA content (fig.4). 
 
 
 
Figure 4: mitochondrial DNA content in C2C12 cells treated for 60 hours 
with vehicle, SAHA 5µM, MS275 5µM and MC1568 5µM. Real Time QPCR 
was performed using NADH Dehydrogenase 1 as mtDNA template, and 
Cyp7a1 promoter region as nuclear DNA. (***p<0.001) 
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Class I HDACs induce a transcriptional reprogramming towards a 
more oxidative phenotype in C2C12 myotubes. 
 
In order to understand how class selective HDAC inhibitors affect 
oxidative metabolism, we performed a microarray analysis in 
differentiated C2C12 cells. The myotubes were exposed to the pan 
inhibitor SAHA, the Class I HDAC selective inhibitor MS275 and the Class 
II HDAC selective inhibitor MC1568. 
The whole genome wide analyses revealed that SAHA regulates 1574 
genes, MS275 1152 genes, and MC1568 only 155 genes (fig.5). 
 
 
 
 
Figure 5: differentially expressed genes in C2C12 myotubes after 
treatment with SAHA, MS275 and MC1568. 
 
 
 
Among all the pathways analyzed, we observed that SAHA and MS275 
treatments significantly regulate more than 10% of the genes belonging 
to metabolic pathway. On the other hand, MC1568 affect only 7 metabolic 
genes. Interestingly, SAHA and MS275 shared 61 genes. About this 
subset, we defined different biological processes and we founded that 
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more than 50% of these genes belong to carbohydrate and lipid 
metabolism (fig. 6). 
 
 
 
Figure 6: left. Venn Diagram of the differentially expressed genes 
belonging to the KKEGG pathway “Metabolic genes” of SAHA, MS275 and 
MC1568 groups. 
Right. Cake presenting the biological processes  of the 61 genes shared by 
SAHA and MS275. 
 
 
 
We validated the microarray data by QPCR and we found that different 
transcription factors, such as PGC-1α, the master regulator of 
mitochondrial biogenesis, Tfam and Tfb1m, the two main transcription 
factors of mitochondrial DNA, were upregulated. In addition we founded 
that several OXPHOS genes (Cox7a1, Cox5a, Cox6a1 and ETFDH), but 
also different genes involved in glucose (Glut4, Glut1, Pdk4, Pkm2), lipid 
(Lcad and Hadh) and TCA cycle (Idh3α, Mdh2, Suclg1 and Bckdhb) were 
similarly regulated by SAHA and MS275 treatments, while MC1568 was 
ineffective (fig.7). 
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Figure 7: gene expression profile of transcription factors and coregulators, 
OXPHOS genes, glucose, lipid, TCA cycle in C2C12 myotubes after 
treatment with SAHA, MS275 or MC1568. Statistical comparison of these 
totals was made using ANOVA. *p<0.05, **p<0.01,***p<0.001. 
 
 
 
Notably, most of the genes analyzed are related to mitchondrial function 
and activity, such as PGC-1a, Tfam, TFB1M, and others. In order to test if 
these compounds could affect mitchondrial function we generated stable 
C2C12 cell line expressing luciferase gene under the control of a PGC-1α 
responsive region of the Tfam promoter. As shown in figure 8, in stable 
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engineered C2C12 myotubes, SAHA and MS275 increased PGC-1α driven 
luciferase activity. As expected, MC1568 treatment did not increase 
luciferase activity indicating that it does not influence PGC-1α expression 
and consequently mitochondrial function (fig.8) 
 
 
 
Figure 8: Stable C2C12 transcfected with TfampromLuc reporter plasmid 
and treated with HDACi for 24 hours. Statistical comparison of these totals 
was made using ANOVA. ***p<0.001. 
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Class I selective HDACi reduce glycemia, insulin levels and glucose 
clearence in Db/Db mice. 
 
To substantiate our in vitro results, we further test the effects of HDACi in 
a genetic mouse model of metabolic disorder, such as the diabetic mice 
Db/Db. Mice were treated every other day with the indicated compounds 
for a total of 20 days. As reported in figure 9, mice receaving MS275 at 
the end of the experiment showed a significant reduction in body weight, 
while other treatment did not affect this paramenter, despite a 
comparable food consumption (fig. 9). 
 
 
Figure 9: DbDb mice treated for 23 days with different HDACi. Left. Body 
weight measured in fasted mice before sacrifice. (N=10) 
Right. Food consumption measurement was repeated 3 times for a period 
of 3 days every time for every cage. (N= 3 cages / treatment). Statistical 
comparison of these totals was made using ANOVA. ***p < 0.001. 
 
 
 
Interestingly, we observed a dramatic reduction in fasted glycemia in 
animals treated with SAHA and MS275, but not with MC1568. In parallel 
with the reduced plasma glucose levels we observed a  reduction in the 
insulin plasma levels and in the homeostatic model assessment (HOMA-
IR) in the MS275 treated gruop. We detected similar effects in the HOMA-
IR of the SAHA treated group, even if plasma insulin did not change 
significantly (fig.10). 
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Figure 10: Blood glucose, insulin levels and HOMA index in DbDb mice 
treated with HDACi. Glucose was measured in fasted mice before sacrifice. 
The HOMA index, or homeostatic model assessment, is a method used to 
quantify insulin resistance (HOMA-IR= (fasted glucose (mg/dl) x fasted 
insulin (mU/L)) / 405). statistical comparison of these totals was made 
using ANOVA. *p < 0.05, **p<0.01, ***p<0.001. 
 
 
 
We also performed a glucose tolerance test and an insulin tolerance test 
which demonstrate the increased glucose clearence and insulin 
sensitivityin mice treated with SAHA and MS275, but again MC1568 fails 
(fig.11) 
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Figure 11: intraperitoneal Glucose Tolerance Test in DbDb mice treated 
with HDACi. Mice were fasted for 16 hr, and glucose levels from tail-vein 
blood were determined before and 30, 60, 90, and 120 min after i.p. 
injection of glucose (2 g/kg). For ITT, random fed mice were injected i.p. 
with insulin (2 U/kg). Glucose levels were determined before and 30, 60, 
120, 180, and 210 min after injection. Statistical comparison of these 
totals was made using ANOVA. *p < 0.05. 
 
 
 
We did not detect any changes in  total cholesterol and plasma bile acids 
levels. Surprisingly FPLC profile reveals an important reduction in VLDL 
pick in SAHA and MS275 treated groups, due to a decrease in associated 
triglycerides, as confirmed by triglycerides quantification in FPLC fractions 
(FIG.12). 
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Figure 12: Plasma cholesterol and plasma bile acids quantifications. 
Cholesterol and triglycerides distribution in plasma lipoprotein fractions 
determined by FPLC. One-ml fractions were collected and assayed for 
cholesterol using an enzymatic kit. (N= 10)  
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Finally to exclude liver dysfunction we performed histological analysis of 
the liver in mice treated with SAHA and MS275 and we observed a strong 
reduction in  lipid accumulation after MS275 treatment improving liver 
phenotype. SAHA treatment also showed a  reduction in lipid droplet size, 
even if lipid accumulation in the liver is not completly reverted (fig.13). 
Consistent with this observation, we mesured the plasma transaminases 
levels and we founded that none of the compounds raise ALT and AST 
levels, actually MS275 treatment reduce significantly their levels (fig.13). 
 
 
 
Figure 13: Hematoxylin and eosin staining reveals an improvement in liver 
phenotype in the MS275 treated group and, in a lesser degree, in the 
SAHA treated group. As consequence of the improvement of liver 
functionality, ALT and AST were reduced in the mice treated with MS275; 
statistical comparison of these totals was made using ANOVA. *p < 0.05. 
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Class I HDAC inhibitors increase energy expenditure in Db/Db 
mice. 
 
Based on the results previously described, we performed metabolic cage 
analysis on animals treated with vehicle, SAHA and MS275 in order to 
verify which metabolic parameters were affected by the compounds 
directly in the living animals. Mice were individually housed and allowed to 
acclimate in the experimental cages with free access to food and water. 
Animals were maintained on 12 hr light/dark cycles. After acclimatation 
we started recording oxygen consumption, CO2 production, heat 
production and activity. 
Although SAHA treatment did not affect any of the parameters recorded, 
we found that MS275 treated mice significantly consume more oxygen 
and produce more CO2 during the dark cycle. No changes were detected in 
the activity of the mice (fig.14). 
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Figure 14: Effect of HDACi on Energy Expenditure in Diabetic Mice. 
Oxygen consumption, CO2 production, and activity were measured over 3 
days by indirect calorimetry. Data on heat production (calculated from gas 
exchange data; kcal/mass/time), VO2 (volume of oxygen consumed; 
ml/mass/time), VCO2 (volume of CO2 produced; ml/mass/time) and 
activity (XYZ coverage; total activity counts) were analyzed using the 
OxymaxWin v3.01 software package. Statistical comparisons of repeated 
measurements were made using ANOVA. In the graphs data are 
expressed as area under the curve (AUC) calculated for the light and the 
dark period over the 3 recording days; statistical comparison of these 
totals was made using ANOVA. *p < 0.05. 
 
 
 
These changes reflect a reduction in the respiratory exchange ratio 
(VCO2/VO2) indicating that mice preferentially use fat as fuel source 
(fig.15).  
 
 
 
Figure 15: Effect of HDACi on Respiratory Exchange Ratio in Diabetic Mice. 
In the graphs data are expressed as area under the curve (AUC) over the 
3 recording days; statistical comparison of these totals was made using 
ANOVA. ***p < 0.001. 
 
 
 
Finally we observed that in mice treated with MS275 the heat production 
was increased. Since the heat production is an indirect measurement, we 
confirm this result evaluating the rectal temperature of  the different 
groups of  animals. Indeed we found an increased body temperature in 
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fasted mice treated with MS275, suggesting  a possible role of brown fat 
(fig.16). 
 
 
 
 
Figure 16: Effect of HDACi Heat production in Diabetic Mice. Data on heat 
production (calculated from gas exchange data; kcal/mass/time) were 
analyzed using the OxymaxWin v3.01 software package. Statistical 
comparisons of repeated measurements were made using ANOVA. In the 
graph data are expressed as area under the curve (AUC) calculated for 
the light and the dark period over the 3 recording days; statistical 
comparison of these totals was made using ANOVA. *p < 0.05. 
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Effects of HDAC inhibitors in target tissues of Db/Db mice 
 
Skeletal muscle  
 
In order to understand the effects of SAHA and MS275 in different 
metabolic tissues we performed genome-wide analyses in two different 
muscle types, gastrocnemuis, a mixed fiber, and vastus lateralis, a 
classical white fiber, in the liver and in white and brown adipose tissues. 
Subsequently, we validated all the microarray analyses by QPCR. In all 
tissues analyzes we found a reprogramming of the gene expression profile 
of relevant genes involved in metabolism and its regulation. 
In particular, in gastrocnemius muscle, we first checked that HDACi 
reached the tissue and inhibit thei targets (fig.17), next we observed an 
increased expression of general transcription factors associated to 
mitochondria (PGC-1α and β, ERRα, Tfam and TFB1M) and genes in the 
glicolysis (PKM2), fatty acid oxidation (LCAD), TCA cycle (IDH3α, SUCLG1) 
and oxidative  phosphorylation (CYT C, COX6A1 and ETFDH) (fig.18). 
 
Figure 17: Western Blot analyses of acetyl-Tubulin and Acetyl-Histone H3 
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Figure 18: effects of HDACi on gene expression profile in gastrocnemius 
muscle. Statistical comparison of these totals was made using ANOVA. 
*p<0.05, **p<0.01,***p<0.001. 
 
 
 
Similar effects in gene expression profile were also observed in two other 
muscle fibers, such as vastus lateralis and soleus, respectively a white 
fiber and a red one. 
Even in these cases we observed an increase in genes involved in 
mitochondrial biogenesis andan increase of classical mitochondrial 
markers, such as Cyt C or COX6A1. Finally, even in these muscle we 
found an increase in metabolic genes, like LCAD or PKM2. (fig.19). 
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Figure 19: effects of HDACi on transcription factors and cofactors, 
metabolic and OXPHOS genes in vastus lateralis and soleus. Statistical 
comparison of these totals was made using ANOVA. *p<0.05, 
**p<0.01,***p<0.001. 
 
 
 
All these data suggest an improved oxidative metabolism and to confirm 
these observation we analyzed the muscle oxidative capacity trough 
succinate dehydrogenase (SDH) staining of gastrocnemius fibers(fig.20).  
As shown in figure 20 MS275, and SAHA to a lesser degree, increase the 
proportion of dark brown fibers, indicating an increased oxidative capacity 
of gastrconemius muscle.  The shift toward more oxidative fibers occurred 
without any changes in typical markers of type I an II fibers (fig.21). 
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Figure 20: succinate dehydrogenase staining in gastrocnemius muscle of 
DbDb mice treated with SAHA or MS275 comare to the vehicle group. 
Arrows indicate darker fibers, indicating more oxidative capacity. 
 
 
Figure 21: QPCR analysis on Troponin 1 and 2 expression, markers of type 
I and II fibers. Statistical comparison of these totals was made using 
ANOVA. *p<0.05, **p<0.01. 
 
 
 
Furthermore, we also used Periodic acid-Schiff stain (PAS) to detect 
glycogen in gastrocnemius muscle. Interestingly we observed different 
behaviors between SAHA and MS275 groups; in particular, SAHA 
treatment reduced glycogen accumulation, while MS275 treated mice 
showed more glycogen storage compare to the vehicle treated group 
(fig.22). In addition, Gomori trichrome staining highlighted ragged red 
fibers in control group indicating mitochondrial myopathy which appear to 
be reduced by SAHA  and MS275 treatments (fig.22). 
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Figue 22: PAS and Gomori Trichrome stainings in gastrocnemius muscle of 
DbDb mice treated with HDACi. 
 
 
Finally, we did not observe any toxicity of the treatments in the  
gastrocnemuis muscle, as showed by alkaline phosphatase (ALP) and 
esterase stainings where we did not found any difference among the three 
different groups. (fig.23) 
 
 
 
Figure 23: esterase ad alkaline phosphatase stainings in gastrocnemius 
muscle of DbDb mice treated with HDACi. 
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Brown Adipose Tissue (BAT) 
 
In order to explain the increased body temperature in MS275 treated 
group, we performed gene expression profile in brown adipose tissue and 
we found that class I selective inhibition significantly increases the 
expression of  classical markers of brown fat, such as UCP1, ELOVL3, 
DIO2, CIDEA and PRDM16(fig.24). Interestingly we observed also an 
increased expression of the β3 subunit of the adrenergic receptor, 
suggesting an increase of the brown fat functionality. 
 
 
 
Figure 24: gene expression profile in brown adipose tissue of DbDb mice 
treated with HDACi or vehicle. Statistical comparison of these totals was 
made using ANOVA. *p<0.05, **p<0.01,***p<0.001. 
 
 
 
Moreover, as for the muscle tissues, in the MS275 group we detected a 
significant increased expression of PGC-1a, PGC-1b and of typical markers 
of mitochondrial biogenesis, as Tfam, TFB1M and Cyt C (fig.25). 
 
 
 
Figure 25: gene expression of transcription factors, cofactors and 
metabolism related genes in brown adipose tissue of DbDb mice treated 
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with HDACi or vehicle. Statistical comparison of these totals was made 
using ANOVA. *p<0.05, **p<0.01,***p<0.001. 
 
 
 
SAHA treatment seems to be less effective, even if it shows a tendence to 
increase the gene expression of classical markers of brown fat (fig.24). 
In addition, hematoxylin and eosin staining reveals a reduced cell size 
after SAHA and MS275 treatments (fig.26). These data, considering the 
increased expression of the adrenergic receptor, suggest an improved 
brown fat phenotype.  
 
 
 
 
 
Figure 26: Upper panel. Hematoxylin and Eosin staining of brown adipose 
tissue in DbDb mice treated with HDACi or vehicle. Lower panel. 
Measurement of the adipocyte cell size in brown fat.Statistical comparison 
of these totals was made using ANOVA. *p<0.05, **p<0.01. 
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White Adipose Tissue (WAT) 
 
White fat is another tissue playng a key role in energy balance. In order 
to understand if HDACi treatments affected metabolic parameters and 
transcription also in this district, we performer QPCR and histological 
analysis. 
As for the trascriptional expression profile in muscle tissues and brown 
fat, even int the WAT we observed an upregulation of genes involved in 
mitochondrial biogenesis, such as PGC1α, Tfam and Cyt C. 
 
 
 
Figure 27: QPCR expression of mitochondrial regulators and markers in 
white adipocyte from DbDb mice treated with HDACi or vehicle. Statistical 
comparison of these totals was made using ANOVA. *p<0.05, **p<0.01. 
 
 
 
Consistent with the results reported above, we also observed that several 
genes involved in lipid metabolism were upregulated, such as the lipid 
fatty acid transporters CD36 and CPT1b, the long chain acyl-CoA 
dehydrogenase LCAD, the hormone-sensitive lipase HSL and the 
uncoupling protein 3 (fig.28). 
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Figure 28: Lipid metabolism gene expression profile in white adipocyte 
from DbDb mice treated with HDACi or vehicle. Statistical comparison of 
these totals was made using ANOVA. *p<0.05. 
 
 
 
We also checked the classical markers of adipose tissue and we observed 
that all of these were upregulated after treatment with MS275, indicating 
a more physiological profile. In order to substantiate the improved fat 
phenotype, we analyzed the expression of typical markers of inlammation 
and we saw that the expression of the iNOS was dramatically reduced, 
confirmig the hyothesis of the improved fat functionality. Also PTGS2 was 
reduced, even if not significantly, while TNFα did not change (fig.29). 
 
 
 
Figure 29: adipose tissue markers and inflammation markers expression 
levels in white adipocyte from DbDb mice treated with HDACi or vehicle. 
Statistical comparison of these totals was made using ANOVA. *p<0.05. 
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Finally hystological analysis confirmed the gene expression profile results. 
In fact hematoxylin and eosin staining revealed a lower cells size of 
adipocytes in the MS275 group, probably due to the increase in lipid 
catabolism and the immunohistochemistry assay against MAC1, a typical 
marker of macrophage recruitment, in the peripheral district appeared 
strongly reduced in mice treated with MS275 and, in a lesser degree, also 
in the SAHA treated group (fig.30). 
 
 
 
 
 
Figure 30: top. Hematoxylin and eosin staining od white adipose tissue in 
DbDb mice treated with vehicle, SAHA or MS275 (magnification 20X). 
Center. Adipocyte cell size measurement of adipocytes. Bottom. 
Immunohistochemistry of white adipocytes against MAC1 (Magnification 
10X). Statistical comparison of these totals was made using ANOVA. 
***p<0.001. 
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Treatment with Class I HDAC inhibitor induce Brown-like 
phenotype in white adipocyte 
 
Transcriptome analysis in visceral fat showed that treatment with Class I 
selective HDAC inhibitor MS275 promotes the expression of classical 
markers of brown adipocyte differentiation. The heatmap in figure 31 
shows that more than 90% of the genes belonging to the GO Biological 
process Brown fat cell differentiation is upregulated after treatment with 
MS275. In contrast, very small differences can be observed after 
treatment with SAHA. (Fig. 31) 
 
 
 
Figure 31: Heatmap of the biological process Brown fat cell differentiation. 
MS275 seems to promote the expression of the entire pathway, 
suggesting a brown like phenotype in white adipocyte. 
 
 
 
In order to confirm the microarray analysis we performed QPCR assays on 
visceral WAT and we observed  that the most typical markers of BAT, such 
as Dio2, Elovl3, Cidea, the uncoupling protein UCP1 and the Adrenergic 
Receptor subunit beta 3. MS275 treated adipocytes remained negative for 
PRDM16: this suggest a brown like phenotype, or a "brite adipocyte" 
phenotype as described by Nedergaard and colleagues (Fig. 32). 
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Figure 32: gene expression of brown fat cell markers in white adipose 
tissue of DbDb mice treated with HDACi or vehicle. Statistical comparison 
of these totals was made using ANOVA. *p<0.05,***p<0.001. 
 
 
 
We also checked the presence of the UCP1 in the visceral WAT by 
immunohistochemistry and we founded that in the MS275 treated group 
UCP1 appears to be strongly increased. Also the white adipose tissue of 
the SAHA treated group is positive for the uncoupling protein UCP1, even 
if in a lesser degree compare to the MS275 treated group. (Fig. 33) 
 
 
 
Figure 33: Top. UCP1 staining in paraffin embedded sections of visceral 
WAT of Db/Db mice treated with HDACi or vehicle. Bottom. Multilocular 
adipocyte founded in the UCP1 stained section of the MS275 treated 
mouse (Brown like or "Brite adipocyte"). 
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Recent experimental evidences reported in the literature have revealed 
that the control of metabolic pathways occurs at the transcriptional level 
also by means of epigenetic mechanisms, and particularly through 
chromatin remodeling224. This discovery has relevant implications and may 
lead to a more comprehensive understanding of physiologic situations as 
well as of metabolic diseases such as obesity, diabetes and metabolic 
syndrome. At this regard, liver, skeletal muscle, brown and white fat 
represent the main target tissues subjected to metabolic control. 
Chromatin acetylation is undoubtedly the main epigenetic mechanism 
through which gene expression can be regulated, therefore, histone acetyl 
transferases (HATs) and especially histone deacetylases (HDACs) most 
likely play a major role in chromatin remodeling. For example, it has been 
demonstrated that HDACs play a central role in the development and 
remodelling of skeletal muscle myofiber225,226. In addition, Gao and 
coworkers recently published that sodium butyrate, a HDAC inhibitor, 
improves insulin sensitivity and increases energy expenditure in mice fed 
with a high fat diet212. 
Although the involvment of these enzymes in the regulation of these 
processes has been clearly demonstrated, it is still unclear which class of 
HDACs is mainly involved and how HDACs can affect the metabolic profile 
of different tissues. 
To address these questions, in this study we examined the effects on 
energy metabolism of different histone deacetylase inhibitors (HDACi). In 
particular we used the well known pan inhibitor SAHA, the Class I HDAC 
inhibitor MS275 and the MC1568, a Class II HDAC inhibitor, using in vitro 
and in vivo approaches. 
 
 
HDACi promote mitochondrial biogenesis in C2C12 myotubes. 
 
In a cellular model of skeletal muscle we observed that the treatments 
with the pan-inhibitor SAHA or with the Class I selective inhibitor MS275, 
but not with the Class II HDAC inhibitor, were able to promote 
mitochondrial biogenesis, probably through a PGC-1α-dependent 
mechanism. In fact, after treatment with SAHA and MS275, the 
expression of PGC-1α was strongly upregulated and this led to increase 
mitochondrial density, activity and mitochonadrial DNA content. 
In addition, experiments using clones stably expressing the luciferase 
gene under the transcriptional control of the PGC-1α responsive region of 
the Tfam promoter, indicated that the treatment with the pan inhibitor or 
with the Class I HDAC inhibitor increases the trancriptional activity of the 
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Tfam promoter, sustaining the hypothesis that HDACi act through a PGC-
1α dependent mechanism. 
We also characterized the effects of these compounds in C2C12 
performing a genome-wide analysis: we found that SAHA and MS275 
increase, respectively, the expression of 128 and 92 genes belonging to 
the KEGG pathway of metabolic processes and among these genes, more 
than 50% are involved in glucose and lipid metabolism, such as GLUT4, 
LCAD, IDH3α and the ETC proteins COX7A1, COX5A or COX6A1.  
In contrast, MC1568 affected only 7 genes in the KEGG pathway of the 
metabolic processes, indicating that probably Class II HDAC activity is not 
directly involved in the regulation of the energy metabolism and 
mitochondrial biogenesis. Class IIa HDACs possess only minimal histone 
deacetylase activity202, and this can contribute to explain the very small 
effects that we observed in cells treated with class II selective inhibitor. In 
addition, class IIb HDACs act on extranuclear targets that are probably 
less involved in metabolic regulation; therefore it is not surprising that 
their inhibition in C2C12 cells minimally affects gene transcription. 
Different results were obtained by using a genetic approach, as in the 
case of the work by Potthoff and coworkers225. The knock-out allows to 
completely delete the expression of the proteins; in that case, the 
repressive complex in which HDACs are recruited, are totally disrupted. 
Instead, using a biochemical inhibition, it is possible to modulate the 
activity of the enzymes, thus HDACs are still present in the cells and can 
still interact with factors and cofactors. 
Collectively, these results reveal that HDACs, and in particular Class I 
HDACs, can affect mitochondrial biogenesis and that the inhibition of its 
activity may drive the cells towards a more oxidative phenotype. 
 
 
HDACi reduce glycemia in diabetic obese mice. 
 
In order to understand whether HDACi can promote mitochondrial 
biogenesis in vivo, we treated insulin resistant obese mice (Db/Db), an 
animal model of diabetes, with SAHA, MS275 and MC1568. 
After SAHA and MS275 treatments, but not after MC1568 treatment, mice 
showed a reduced glycemia (-50%); moreover, only MS275 induced a 
reduction of obesity (-8% of total body weight) and of the plasma insulin 
levels (-75%) in treated mice. In addition, SAHA and MS275 improved the 
glucose tolerance, suggesting an increase in insulin sensitivity. Based on 
these results, we performed CLAMS analysis on SAHA and MS275 groups 
and we demonstrated that mice treated with Class I HDAC selective 
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inhibitor increase energy expenditure and oxygen consumption. This may 
be due to the improved ability to burn substrates, such as glucose or fatty 
acids. In fact, MS275 group showed also a significant reduction in the 
respiratory exchange ratio, suggesting that these mice use preferentially 
fat as energy source. Since the locomotor activity is comparable among 
the groups, these data indicate that MS275 treated mice have an 
increased basal metabolism, and this correlates with increased heat 
production following MS275 administration, suggesting an effect of this 
compound on brown adipose tissue. 
The ability of MS275 treated mice to better use and store substrates is 
also suggested by the reduced body weight and the increased glycogen 
storage in muscle. Moreover, skeletal muscle is one of the main tissues 
which can use fatty acids as energy source. Notably, in diabetic subjects, 
intracellular lipid accumulation causes reduced mitochondrial oxidative 
capacity in skeletal muscle227,228. The reduction of respiratory exchange 
ratio in diabetic mice treated with MS275 could indicate an increased 
mitochondrial function in skeletal muscle (see below), which uses fatty 
acids to produce ATP and stores glucose in the form of glycogen. In 
agreement with this, MS275, and SAHA in a lesser degree, reduced not 
only glucose but also plasma triglycerides. 
HDACi treatments did not reduce food intake or locomotor activity, 
indicating that there was no toxicity from these compounds; this is 
corroborated by the plasma transaminases levels which appeared even 
lower after treatment with MS275. These results indicate an improvement 
in liver function, in which lipid accumulation resulted dramatically reduced 
after treatment with MS275 and SAHA, even if to a lesser degree. 
In summary, in a diabetic mouse model, treatments with HDAC pan-
inhibitor or Class I inhibitor reduce glycemia, plasma triglycerides and 
hepatic lipid accumulation; in addition, Class I HDAC inhibitor 
administration reduces obesity, increases energy expenditure and heat 
production. 
 
 
Class I HDAC inhibition promotes mitochondrial biogenesis in 
skeletal muslce. 
 
Skeletal muscle constitutes the 40% of the total body weight and, for this 
reason, it plays a central role in fatty acid utilisation and glucose 
homeostasis. At this regard, mitochondria are particularly important for 
skeletal muscle function, given also the high oxidative requests imposed 
on this tissue by contraction. 
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In order to explain the changes in blood chemistry and in metabolic 
parameters observed in mice, we performed gene expression analysis in 
three different muscle fibers; in particular we focused our attention on 
gastrocnemius, a muscle in which both type I and type II myofibers are 
present, on soleus, where type I fibers are predominant, and on vastus 
lateralis that, in contrast, is mainly constituted by type II fibers.  
Collectively, in all the muscles analyzed, we found that, in mice treated 
with the Class I HDAC selective inhibitor, mitochondrial markers were 
upregulated as well as central enzymes belonging to glucose and fatty 
acid metabolism. These results support the hypothesis that the inhibition 
of Class I histone deacetylase promote oxidative metabolism and can 
contribute to explain the reduced glycemia, the reduction in plasma 
triglycerides and the increased oxygen consumption observed in these 
mice. 
Skeletal muscle is the largest insulin-sensitive organ in humans, 
accounting for more than 80% of insulin-stimulated glucose disposal. 
Thus, insulin resistance in this tissue has a major impact on whole-body 
glucose homeostasis; one possible mechanism by which impaired 
mitochondrial function might contribute to insulin resistance is through an 
altered metabolism of fatty acids. The increased expression of OXPHOS 
genes following treatment with MS275 and SAHA, even if to a lesser 
degree, could improve fatty acid metabolism and mitochondrial function, 
increasing insulin sensitivity in muslce. 
Succinate dehydrogenase (SDH) staining of sections of gastrocnemius 
corroborates the previuosly described results; in fact in mice treated with 
MS275, but also in the SAHA treated group to a lower extent, SDH 
staining revealed darker myofibers compared to the control group, 
indicating a more oxidative capacity of the myofibers. This switch towards 
fat utilisation, besides increasing insulin sensitivity, leads to increased 
glucose uptake and storage in the form of glycogen. 
Moreover, mitochondrial dysfunction and morphological alterations 
highlighted by trichrome staining appeared strongly reduced after MS275 
treatment, indicating again that inhibiting Class I HDAC it is possible to 
modulate mitochondrial biogenesis and function. 
Interestingly, we did not observe any change in the expression of type I 
or type II troponins, indicating that the metabolic switch does not 
correlate with a reprogramming in muscle fiber types, as observed in 
previously published works212,221,225. This suggests that HDACi act at the 
level of the metabolic adaptation of mature skeletal muscle, without 
interfering with the myofiber differentiation. 
Collectively, these data indicate a role of Class I HDACs in modulating 
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mitochondrial biogenesis and oxidative metabolism in skeletal muscle. 
 
 
Class I HDAC inhibition reduces brown adipocyte size and 
improves brown fat functionality. 
 
The role of mitochondria in adipose tissue is most apparent in brown 
adipose tissue, where flux through the ETC generates heat in the process 
of thermogenesis, a potentially important mechanism regulating systemic 
metabolism120-123. 
After MS275 administration, in brown adipose tissue we found an increase 
in the expression of PGC-1α, Tfam and mitochondrial markers, indicating 
an induction of mitochondrial biogenesis. In addition, in parallel with the 
induction of mitochondrial biogenesis, we observed that HDACi 
significantly increased expression of the insulin dependent glucose 
transporter; even in this case, these data suggest an increased insulin 
sensitivity and can contribute to explain the reduced glycemia observed in 
SAHA and MS275 treated groups. 
Moreover, brown adipocytes appeared smaller and showed an increase in 
the expression of the typical markers of brown fat, such as UCP1, DIO2, 
ELOVL3 and CIDEA. The increased expression of the beta 3 subunit of the 
adrenergic receptor (ADRB3), after MS275 treatment, leads to 
hypothesize that brown fat, which is totally dysregulated in Db/Db mice, 
besides being more differentiated, can be also more functional; this 
increase in brown fat functionality could be responsible for the increase in 
the heat production and the increased body temperature detected in these 
mice. 
In this tissue, the treatment with SAHA appeared to be less effective than 
MS275 in promoting mitochondrial biogenesis; nevertheless, brown 
adipocytes from SAHA treated mice resulted significantly smaller with 
respect to the vehicle treated mice and typical brown fat markers also 
showed a tendency to increase. 
Taken together these results indicate that brown fat morphology and 
functionality are affected by HDACi and, in particular, that inhibitinig Class 
I HDACs it is possible to promote thermogenesis and energy expenditure. 
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Inhibition of class I HDAC promotes mitochondrial biogenesis and 
energy expenditure in white adipocytes. 
 
Mitochondrial content in white adipocytes is decreased in both rodent and 
human obesity147,155-158 and correlates with insulin resistance that 
accompanies obesity. In mice treated with MS275 we found an increased 
expression of PGC-1α and a consequent increase in Tfam expression. This 
suggests that, even in the white adipose tissue, by inhibiting class I 
HDACs it is possible to induce mitochondrial biogenesis. In addition, we 
also observed a general increased expression of genes involved in lipid 
metabolism, such as the fatty acid transporters CD36 and CPT1b or the 
hormone-sensitive lipase HSL. 
Moreover, it has been demonstrated that adipocyte hypertrophy is 
associated with insulin resistance229; following MS275 treatment, mice 
showed a significant reduction in white adipocyte size and, in addition, a 
reduced macrophage recruitment into the tissue, followed by a decreased 
expression of some inflammatory markers. These data indicate that the 
inflammatory status of white fat is probably reduced and this could lead to 
an improvement in insulin signaling and adipokine expression in white fat. 
White adipocytes display a high degree of plasticity138, and regional 
differences in metabolic activity can be linked to varying mitochondrial 
density139. Higher mitochondrial density and even UCP1 expression can be 
induced in response to pharmacological or genetic alterations of white 
adipocytes139-148, suggesting that white adipose tissue could potentially be 
induced to acquire more oxidative metabolic phenotypes, promoting 
increased fuel consumption and, thus, energy expenditure. 
In mice treated with MS275, microarray analysis revealed a general 
induction of the genes belonging to the brown fat differentiation pathway, 
which includes 29 genes such as the adrenergic receptor beta subunit 1, 2 
and 3, the transcriptional factor C/EBPα, β and PRDM16, the nuclear 
receptor PPARγ, the fatty acid binding protein 4 (FABP4 or AP2), the 
glucose transporter GLUT4 and the uncpoupling protein 1 (UCP1). In 
agreement with this observation, we found that white adipocytes, 
following MS275 treatment, were positive to the uncoupling protein 1 and 
to classical markers of brown fat, such as DIO2, ELOVL3 and ADRB3. 
Nevertheless these cells remained negative for PRDM16, the main 
transcription factor regulating brown adipocyte differentiation, suggesting 
that they did not transdifferentiate to brown adipocytes. Thus, it is 
possible that the inhibition of class I histone deacetylases induced a 
brown-like phenotype, or "brite phenotype", as observed for example 
after chronic somministration of rosiglitazone in primary cultures of white 
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adipocytes148. 
In summary, in white adipose tissue, Class I HDAC inhibition regulates 
lipid accumulation, reduces inflammation and promotes energy 
expenditure by increasing mitochondrial biogenesis and UCP1 expression. 
 
 
Conclusions. 
 
These results confirmed a role of mitochondrial dysfunctions in metabolic 
disorders; by promoting oxidative metabilsm in vivo it is possible to 
increase energy expenditure and ameliorate the obese and diabetic 
phenotype.  
For the first time we demonstrated a mitochondrial signature assignable 
to class I HDACs. Class I histone deacetylases participate in the regulatory 
network of mitochondrial biongenesis and their biochemical inhibition can 
promote oxidative metabolism in vitro and in vivo in different tissues. 
HDAC inhibitors could be valuable tools to understand dysregulated 
mechanisms at the basis of metabolic dysfunctions, and histone 
deacetylases may have potential application in the prevention and 
treatment of metabolic syndrome. 
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